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Chronic valvular heart disease (CVHD) is common in Cavalier King Charles spaniel 
(CKCS) and has the potential to affect platelet activation or function.  
 
The present study objective was to determine platelet closure time, mean platelet 
component (MPC) concentration and platelet component distribution width (PCDW) 
in dogs with subclinical CVHD, and to assess the factors influencing these 
variables. A second objective was to assess platelet count, MPC concentration, 
PCDW, mean platelet volume (MPV), platelet volume distribution width (PDW), 
plateletcrit (PCT), mean platelet mass (MPM) and platelet mass distribution width 
(PMDW) in CKCS.   
 
Haematological values, closure time, murmur grade and echocardiographic 
variables were recorded in 89 CKCS. Associations between explanatory variables 
(sex, age, murmur grade, echocardiographic variables, platelet count, and 
haematocrit (HCT)) and outcomes (closure time, MPC concentration, and PCDW) 
were examined using multivariate regression analysis. Platelet indices were 
compared between CKCS and a group of 39 control dogs (non-CKCS). 
 
A model with 5 variables best explained variation in closure time (R2, 0.74), with 
greater than 60% of the variance of closure time explained by mitral valve 
regurgitant jet size. The model of best fit to explain variation in MPC concentration 
included only platelet count (R2, 0.24). The model of best fit to explain variation in 
PCDW included platelet count and sex (R2, 0.25). The MPC concentration, MPV, 
PDW, MPM and PMDW values were significantly higher, and the platelet count, 
PCT, PCDW and HCT values significantly lower, in the CKCS compared to control 
dogs.  
 
In the present study, a significant effect of mitral valve regurgitant jet size on closure 
time was consistent with platelet dysfunction. However, platelet activation, as 
determined by MPC concentration and PCDW, was not a feature of subclinical 
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Chronic valvular heart disease (CVHD), characterised by progressive 
myxomatous degeneration and thickening of the mitral valve leaflets, is the 
most common heart disease in dogs (Sisson et al. 1999). This disease is 
particularly common in CKCS, with echocardiographic evidence of mitral 
valve prolapse (MVP) reported in more than 80% of CKCS aged one to three 
years (Pedersen et al. 1999a). 
 
Decreased platelet number and increased platelet size (thrombocytopenia 
and macrothrombocytosis, respectively) are also common in the CKCS 
(Eksell et al. 1994, Smedile et al. 1997, Pedersen et al. 2002, Singh and 
Lamb 2005). Previous studies report the prevalence of thrombocytopenia 
(defined as a platelet count less than 100 x 109/L) as 31-56% (Eksell et al. 
1994, Olsen et al. 2001, Pedersen et al. 2002, Cowan et al. 2004, Olsen et 
al. 2004, Singh and Lamb 2005), with macrothrombocytosis (defined as 
greater than 30% of platelets with diameter ≥ 3µm or greater than 30% of 
platelets subjectively as large as or larger than a red blood cell) present in an 
overlapping 30-33% of dogs (Cowan et al. 2004, Singh and Lamb 2005).  
 
In all species, valvular heart disease has the potential to affect platelet 
activation or function as a result of turbulent high-velocity blood flow and fluid 
shear stress (Brown et al. 1975).  Increased platelet activation and reactivity 
would be expected initially; however, continuous stimulation and stress may 
lead to structural and biochemical changes associated with decreased 
platelet function (Tanaka and Yamane 2000). Alteration of platelet function in 
humans with heart disease contributes to the development of vascular 





There are conflicting reports regarding platelet activation and function in 
dogs with CVHD. A significant increase in closure time has been described in 
CKCS with moderate to severe mitral valve regurgitation (MVR) compared to 
those with minimal or mild regurgitation or healthy control dogs (Tarnow et al. 
2003, 2004, 2005). A significant inverse relationship has also been identified 
between plasma von Willebrand factor (VWF) concentration and regurgitant 
jet size, as well as a relative absence of high-molecular-weight VWF mul-
timers in samples obtained from dogs with moderate to severe MVR (Tarnow 
et al. 2004). Consequently, the prolonged closure time was thought to be a 
result of these quantitative and qualitative changes in VWF rather than an 
alteration of intrinsic platelet function. However, concurrent alteration of 
platelet function or platelet activation could not be excluded. 
 
Enhanced platelet-leukocyte aggregation, which is suggestive of platelet 
activation, has been identified in dogs with congestive heart failure, 
compared with results for age-matched control dogs (Tarnow et al. 2010a). 
In addition, decreased platelet lifespan has been reported in dogs following 
experimental induction of MVR, which would support the presence of 
younger platelets with increased activity (Tanaka et al. 2002). However, 
plasma concentration of thromboxane B2, platelet surface P-selectin 
expression, and thromboelastographic variables are not significantly different 
between CKCS with CVHD and moderate to severe MVR, compared with 
results for affected dogs with absent or minimal MVR or healthy control dogs 
of other breeds (Tarnow et al. 2005, Tarnow et al. 2010b). 
 
Aggregometric studies (Tanaka and Yamane 2000, Olsen et al. 2001, 
Tarnow et al. 2005) have also yielded conflicting results, with increased, 
decreased, and unchanged responses described in CKCS with advanced 
disease, compared with results for those with mild or no disease or healthy 
dogs of other breeds. Reasons for these discrepancies are unclear, but they 
may be explained by differences in laboratory methods, lack of 
standardisation of laboratory techniques, or differences in criteria for the 
classification of disease severity or control dogs. In addition, marked 
interbreed variability has been observed for the maximal aggregation 
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response (Cowan et al. 2004, Nielsen et al. 2007, Moesgaard et al. 2009) 
and breed composition of control groups has differed among studies. There-
fore, in contrast to humans, the extent of platelet activation in dogs with 
CVHD remains uncertain. 
 
Mean platelet component (MPC) concentration, which is measured by use of 
an optical-based haematology analyser, has emerged as a marker of platelet 
activation (Moritz et al. 2005). The MPC concentration is an estimate of 
platelet density, and decreased values are indicative of platelet activation 
(Ahnadi et al. 2004). In dogs, decreased MPC concentrations have been 
detected after exercise, in patients with inflammatory disease, and in 
association with immune-mediated thrombocytopenia (Moritz et al. 2003, 
Moritz et al. 2005, Bauer et al. 2012, Smith et al. 2014). It has been 
suggested that decreased MPC concentration is a more sensitive marker of 
platelet activation compared to P-selectin expression, in part because of the 
persistence of decreased MPC concentrations following activation despite 
the loss of cell-surface P-selectin (Macey et al. 1999, Moritz et al. 2005). The 
standard deviation (SD) of the platelet component concentration, known as 
the platelet component distribution width (PCDW), can also be calculated. 
This index is increased if both degranulated and non-degranulated circulating 
platelets are present, and it is considered another marker of platelet 
activation (Moritz et al. 2005). It is possible that MPC concentration and 
PCDW could provide additional information regarding the activation of 
platelets in dogs with heart disease. 
 
This chapter will review CVHD in the CKCS and its similarities to MVP in 
people; clinical and echocardiographic indices of heart disease severity; 
methods of platelet number, activation and function assessment (with 
reference to previous findings in the CKCS); automated platelet indices 
(including MPC concentration and PCDW) and the reported associations 




1.2 Chronic valvular heart disease in the Cavalier King 
Charles spaniel and other dog breeds 
 
1.2.1 Occurrence, pathology, inheritance and diagnosis 
 
Chronic valvular heart disease, defined as progressive myxomatous 
degeneration and thickening of the mitral valve leaflets, is the most common 
heart disease in dogs (Sisson et al. 1999, Borgarelli et al. 2008) and is 
estimated to account for 75–80% of all heart disease cases in dogs 
(Häggstrӧm and Pedersen 2005).  
 
Mitral valve prolapse is a fundamental and early feature of CVHD, and is 
defined as the protrusion of one or both valve leaflets to the atrial side of the 
plane of the mitral annulus during systole (Pedersen et al. 1999a). The 
degree of MVP correlates with the severity of MVR (Pedersen et al. 1996).  
 
Chronic valvular heart disease has a strong small-breed predisposition. It is 
particularly common in the CKCS and many dogs are affected from a young 
age. In Denmark, ultrasonographic evidence of MVP was present in 82% 
(54/66) of CKCS between one and three years of age and 97% (84/87) of 
CKCS greater than three years of age, with a left apical systolic murmur 
identified clinically in 50% of dogs by 6.2 years (Pedersen et al. 1999a). In a 
French study, there was ultrasonographic evidence of CVHD in 91% 
(139/152) of CKCS of all ages, and a left apical systolic murmur in 50% of 
dogs by 6.6 years (Chetboul et al. 2004). Similarly, an American study 
reported the presence of a left apical systolic murmur in 56% (220/394) and 
100% (10/10) of CKCS aged greater than four and 10 years, respectively 
(Beardow and Buchanan 1993). The latter study also reported that the age of 
referral for assessment of CVHD was lower in the CKCS with a mean age of 
6.25 years compared to a mean age of 12 years in other breeds. 
 
The pathological changes of CVHD are well described and are characterised 
by expansion of the extracellular matrix with glycosaminoglycans and 
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proteoglycans, disruption or loss of the collagen-rich fibrosa layer, and 
change in valvular interstitial cell phenotype (Kogure 1980, Pedersen and 
Häggstrӧm 2000). Morphologically, these changes result in enlargement and 
thickening of the mitral valve leaflets, inter-chordal hooding, elongation of the 
chordae tendineae and MVP (Pomerance and Whitney 1970, Pedersen et al. 
1995). Collectively, these changes result in valve leakage during systole 
(MVR) (Whitney 1974). As CVHD progresses, an increase in left ventricular 
filling pressures associated with volume overload may result in left atrial and 
later ventricular dilation (i.e. eccentric hypertrophy) (Kvart et al. 2002). The 
progression of CVHD is inevitable but typically slow. In some cases, left-
sided congestive heart failure will develop (Lord et al. 2010). 
 
The cause of CVHD in dogs is not known; however, a genetic component is 
suspected based upon the higher prevalence, and results of genealogical 
and genetic studies, in specific breeds (Lewis et al. 2011, Madsen et al. 
2011). Traditionally CVHD has been considered a complex polygenic 
threshold trait; a theory supported by more recent failure to identify 
association with any single major locus in genome-wide association studies 
(Madsen et al. 2011, French et al. 2012). Although traditionally described as 
a progressive, non-inflammatory disease, in recent years it has become 
apparent that canine CVHD is associated with immune system activation. A 
2006 study evaluated genomic expression patterns from the anterior mitral 
valve leaflet of four dogs with severe CVHD using an oligonucleotide 
microarray, and identified uniform activation of several pathways including 
those involved in immunity and inflammation (Oyama and Chittur 2006). 
Based upon this finding, it is possible that the immune system is involved in 
the development and/or progression of CVHD. 
 
A diagnosis of CVHD is commonly based on a combination of cardiac 
auscultation and two-dimensional, M-mode and colour-flow Doppler 
echocardiography (Muzzi et al. 2003). In brief, auscultation of a left-sided 
apical systolic murmur is consistent with MVR; two-dimensional and M-mode 
echocardiography permits identification of abnormal mitral valve thickening 
and prolapse and cardiac remodelling; and colour-flow Doppler 
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echocardiography enables estimation of the mitral regurgitant jet area, 
usually expressed as a percentage of the left atrial area (Pedersen et al. 
1999a, Muzzi et al. 2003). 
 
1.2.2 Disease-related variables of chronic valvular heart disease 
1.2.2.1 Clinical and echocardiographic indices of mitral valve 




Cardiac murmur intensity is most commonly graded using a six point grading 
system, with grades I-IV/VI varying in intensity, and grades V/VI and VI/VI 
characterised by the presence of a precordial thrill and a murmur that is 
audible with the stethoscope lifted off the chest wall, respectively. The 
severity of MVR is positively associated with heart murmur grade on 
auscultation (Ljungvall et al. 2009) and with severity of CVHD (heart failure 
class) (Häggstrӧm et al. 1995). 
 
Colour-flow Doppler echocardiography 
 
The assessment of MVR severity in dogs with CVHD is important because 
mild MVR is clinically insignificant whereas severe regurgitation is 
haemodynamically consequential and associated with increased morbidity 
and mortality (Bonow et al. 1998). 
 
There is lack of a true gold standard in the assessment of MVR severity, with 
inherent advantages and disadvantages of each proposed method (Zoghbi et 
al. 2003). The Proximal Isovelocity Surface Area (PISA) method, a Doppler 
technique commonly used in people to quantify (as opposed to semi-
quantify) MVR has been reported to be an accurate ultrasonographic method 
of estimating the severity of MVR (Kittleson and Brown 2003, Gouni et al. 
2007, Chetboul and Tissier 2012). The PISA method permits assessment of 
the flow rate through the regurgitant orifice, measurement of the regurgitant 
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volume, and calculation of the regurgitant fraction (Chetboul and Tissier 
2012). The PISA method is not routinely used in dogs because it is time-
consuming and technically demanding (Gouni et al. 2007). Other limitations 
of the PISA method are that there is reduced accuracy in the absence of a 
circular orifice and that it cannot be used in the presence of multiple jets 
(which can occur with severe CVHD) (Chetboul and Tissier 2012). 
Furthermore, recently, the PISA method has been shown to be unreliable in 
the presence of eccentric jets, which are found in the majority of 
myxomatous degenerative valvular disease cases (Sargent et al. 2015). 
 
A simpler technique to assess MVR severity is the estimation of the mitral 
regurgitant jet size using colour-flow Doppler mapping. Estimation of the 
mitral regurgitant jet size is typically made from a left parasternal 4-chamber 
view. The method involves frame-by-frame analysis to identify and estimate 
the percentage of the left atrial area, as assessed by eye, occupied by the 
largest mitral jet (Figure 1.1) (Pedersen et al. 1999a, Pedersen et al. 1999b). 
A related, semi-quantitative measurement of mitral regurgitant jet size is the 
area of the regurgitant jet relative to the left atrial area (ARJ/LAA), also 
obtained from a left parasternal 4-chamber view. The latter method involves 
the calculation of the maximum ratio of the regurgitant jet area signal to the 
left atrial area, using colour-flow Doppler echocardiography and 
computerised planimetry (Muzzi et al. 2003, Chetboul and Tissier 2012). A 
disadvantage of both the mitral regurgitant jet size estimation and ARJ/LAA 
methods is the ability of several factors such as arterial blood pressure, left 
atrial pressure, jet orientation, gain settings and pulse repetition frequency to 
influence results (Zoghbi et al. 2003, Gouni et al. 2007). 
 
Despite its limitations, the ARJ/LAA method has been shown to correlate 
with quantitative Doppler techniques including mitral regurgitant volume (r = 
0.81, p < 0.001) (Muzzi et al. 2003), the effective regurgitant orifice area (r = 
0.79, p < 0.001) (Muzzi et al. 2003) and regurgitant fraction (r = 0.58, p < 
0.001) (Gouni et al. 2007) and is therefore a valid option for assessment of 









Figure 1.1: Mitral regurgitant jet size in 3 dogs with varying degrees of 
severity of CVHD.  
Left parasternal 4-chamber view. In Image A the regurgitant jet 
(arrow) is estimated to occupy less than 15% of the left atrial 
chamber, consistent with minimal MVR; in Image B the regurgitant 
jet is estimated to occupy 15% to 50% of the left atrial chamber, 
consistent with mild MVR and in Image C the regurgitant jet is 
estimated to occupy greater than 50% of the left atrial chamber 
consistent with moderate to severe MVR, as previously described 
(Tarnow et al. 2003). LA: left atrium. LV: left ventricle. 
 
1.2.2.2 Echocardiographic indices of left heart remodelling 
 
Persistent and haemodynamically significant MVR results in volume overload 
(Chetboul and Tissier 2012).  
 
Volume overload is first characterised by an increase in left atrial size, which 
is commonly assessed using the left atrial to aortic ratio (LA:Ao), obtained 
from the right parasternal short-axis approach at the level of the aortic valves 

























Figure 1.2: Left atrial to aortic ratios in 2 dogs with varying 
degrees of severity of CVHD. 
Right parasternal short-axis view, at the level of the aortic valve as 
previously described (Thomas et al. 1993). Figure A: American 
College of Veterinary Internal Medicine (ACVIM) canine CVHD 
score A dog with a LA:Ao of 1; reference interval 1.03±0.09 
(Hansson et al. 2002). Figure B: ACVIM canine CVHD score C 
dog with a moderately-markedly dilated left atrium (LA:Ao of 2). 
 
With progression of MVR over time, there is a corresponding increase in 
volume overload that results in enlargement of the left ventricular chamber 
during end-diastole. This left ventricular eccentric hypertrophy, a marker of 
increased pre-load, may produce annular stretching and worsen the severity 
of MVR (O’Gara et al. 2008, Chetboul and Tissier 2012). The diameter of the 
left ventricle during diastole (referred to as the Left Ventricular Diameter 
during Diastole [LVDD]) is a commonly acquired index, obtained using M-
mode echocardiography at the level of the chordae tendineae as guided by a 
2-dimensional right parasternal short axis view (O’Gara et al. 2008, Chetboul 
and Tissier 2012). 
 
The Left Ventricular Diameter during Systole (LVDS) is obtained using the 
same approach as LVDD, and can be used to assess for impaired systolic 
function in advanced CVHD cases (Chetboul and Tissier 2012). An increase 
in LVDS, in spite of enhanced left ventricular ejection into a low pressure left 
atrium during systole, is consistent with systolic myocardial dysfunction 









Left atrial size and left ventricular internal dimensions prior to, and at the 
onset of, congestive heart failure have been reported in 18 CKCS (Lord et al. 
2010). Before the onset of congestive heart failure there was a slow increase 
in left atrial size, LVDD and LVDS until approximately 6-12 months prior to 
the onset of congestive heart failure, at which time there was a rapid rate of 
change suggesting that the rate of increase in left chamber size may be used 
to predict cardiac decompensation (Lord et al. 2010). 
 
1.2.3 Comparative features of canine chronic valvular heart 
disease and mitral valve prolapse in people 
 
It has been proposed that canine CVHD may be a suitable animal model for 
human MVP (Pedersen and Häggstrӧm 2000). 
 
Mitral valve prolapse in people has similar macroscopic and microscopic 
pathological features to CVHD in dogs (Pomerance and Whitney 1970). 
Mitral valve prolapse is a fundamental feature of both diseases (Pedersen 
and Häggstrӧm 2000). Both CVHD and MVP have a suspected genetic 
component, which is considered to be autosomal or polygenic in people 
(Devereux et al. 1982, Wilcken 1992) and polygenic in the dog (Häggstrӧm 
et al. 1992). In both species, there is an increasing prevalence with age 
(Whitney 1974, Davies et al. 1978) and males are at  higher risk than 
females of developing severe disease with increasing age (Davies et al. 
1978, Swenson et al. 1996). There is a MVP disease association with a small 
stature and narrow chest in both dogs and people (Schutte et al. 1981, Olsen 
et al. 1999). Furthermore both MVP and CVHD have a slowly progressive 
disease course (Pedersen and Häggstrӧm 2000). 
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1.3 Platelets and platelet function 
 
1.3.1 Platelet review 
 
1.3.1.1 Platelet function in primary haemostasis 
 
The control of haemorrhage (haemostasis) is essential for maintenance of 
life. Haemostasis is mediated through a complex series of pathways 
culminating in the development of a platelet plug (primary haemostasis) 
followed by the deposition of a stable fibrin clot (secondary haemostasis). 
 
Platelets, or thrombocytes, are disc-shaped, anucleate cytoplasmic 
fragments that play an essential role in primary haemostasis and 
maintenance of vascular integrity (Barger 2003, Drachman 2004). 
 
There are three main components to primary haemostasis that occur 
simultaneously: adhesion, activation and aggregation (Kelley 2013). Primary 




Following vessel damage, circulating platelets contact exposed 
subendothelial collagen and membrane-expressed tissue factor (Tvedten 
2012). Next, the glycoprotein (GP), VWF, assists the adhesion of platelets to 
subendothelial collagen and to each other (Tvedten 2012). Additionally there 
is direct binding of platelets to subendothelial collagen via the integrin α2β1 




Adhesion of platelets to subendothelial collagen initiates platelet activation 
(Kamath et al. 2001). There is activation of the platelet surface collagen 
receptor GP IIb-IIIa, platelet shape change from disc to sphere and 
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pseudopod formation, and release of stored contents from alpha and dense 
platelet granules (refer to Section 1.3.1.2). With activation, platelets 
synthesise and release thromboxane A2. Thromboxane A2 and alpha and 
dense granule contents attract more platelets to the growing platelet plug 
(Tvedten 2012, Brass et al. 2013). Platelet signalling mediates platelet shape 





Platelet aggregation is enhanced due to binding of plasma VWF, fibrinogen, 
and fibrin to activated GP IIb-IIIa (Brass et al. 2013). Aggregation of platelets 
leads to formation of the platelet plug and control of haemorrhage.  
 
An abnormality at any stage in the fibrin clot formation process can result in 
failed haemostasis (Kelley 2013). 
 
1.3.1.2 Platelet structure 
 
Platelet structure is complex and may can be divided into four sections: the 
peripheral zone, the structural zone, the organelle zone and the 
membranous system (Kelley 2013, White 2013). 
 
The peripheral zone forms the most external platelet layer (Kelley 2013, 
White 2013). This section contains the outer platelet membrane, which is 
comprised of a phospholipid bilayer interspersed with specialised proteins 
and GP receptors integral to platelet function (Boudreaux 2008). The 
previously mentioned GP VI and GP IIb-IIIa are examples of GP located 
within this bilayer.  Glycoprotein IIb-IIIa is the most common GP complex 
expressed on the surface of platelets (Boudreaux 2008).  
 
The structural zone of the platelet is located beneath the peripheral zone and 
contains structures required to maintain the disc-shaped form of quiescent 
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platelets during circulation, and change platelet shape during platelet 
activation (Kelley 2013, White 2013). Broadly speaking, the structural zone 
comprises both microtubules and a cytoskeletal network. Microtubules are 
defined as hollow, cylindrical structures, comprising protofilaments with α-β 
tubulin dimer composition. Beta-1 tubulin is the most common tubulin isoform 
and is primarily expressed in megakaryocytes and platelets (Boudreaux 
2008). A mis-sense mutation in the gene encoding β1-tubulin is responsible 
for macrothrombocytopenia in the CKCS (refer to Section 1.3.7.2.3). The 
cytoskeletal network, including actin and myosin, is responsible for 
microtubule contraction (and therefore assists with platelet shape change 
and proplatelet formation), granule movement and release, and thrombus 
retraction during platelet activation (Kelley 2013).  
 
The organelle zone, located beneath the structural zone within the platelet 
cytoplasm, contains mitochondria, glycogen stores and storage granules (of 
which there are three main types: alpha, dense and lysosomal) (Boudreaux 
2008, Kelley 2013, White 2013). Alpha granules are the most sizeable and 
numerous, and contain proteins including β-thromboglobulin (BTG), platelet 
factor 4 (PF4), fibrinogen and VWF (Boudreaux 2008).  Additionally alpha 
granules also contain the trans-membrane proteins GP IIb-IIIa and P-selectin 
(Boudreaux 2010a). Dense granule contents include adenosine diphosphate 
(ADP), GP IIb-IIIa and P-selectin, high concentrations of Ca2+ and serotonin 
(Boudreaux 2010a). 
 
The fourth platelet zone is the membranous system comprising the 
canalicular and dense tubular system (Kelley 2013, White 2013). The 
canalicular system comprises a series of interconnecting channels opening 
to the platelet surface and permitting external release of platelet granule 
contents during platelet activation (Boudreaux 2008). The dense tubular 
system, derived from smooth endoplasmic reticulum is responsible for 




1.3.1.3 Platelet production 
 
Mature megakaryocytes produce platelets via the process of proplatelet 
formation (Kelley 2013). Megakaryocyte maturation, including endomitosis, 
and formation of the demarcation system must occur before proplatelet 
formation can begin (Boudreaux 2010c). The latter involves in-folding of the 
megakaryocyte plasma membrane to create platelet cisternae (Boudreaux 
2010c).  
 
The first stage of proplatelet formation involves centrosome disassembly and 
movement of microtubules to the cell cortex (Italiano and Hartwig 2013). 
Secondly, thick pseudopodia arise from a single megakaryocyte pole 
(Italiano and Hartwig 2013). There is subsequent lengthening of the thick 
pseudopodia to form thin proplatelet processes (Italiano and Hartwig 2013). 
Thirdly the sliding movement of microtubules within thick pseudopodia and 
thin proplatelet processes together with actin-myosin complexes forces 
mediate elongation of these proplatelet processes (Italiano and Hartwig 
2013). Fourthly, within the tips of the proplatelet processes, microtubules 
loop upon themselves and re-enter the shaft to assemble at the proplatelet 
tip (Italiano and Hartwig 2013, Kelley 2013). The tips of the proplatelet 
processes, the main site of platelet assembly, is where microtubule coiling, a 
characteristic of circulating platelets, occurs (Kelley 2013). 
 
Eventually the megakaryocyte cytoplasm resembles a mass of proplatelet 
processes (Italiano and Hartwig 2013). Mature megakaryocytes are located 
close to endothelial cells permitting proplatelet processes to reach marrow 
sinusoids (Boudreaux 2010b). Proplatelet processes are released into the 
blood stream, followed by release of individual platelets from the proplatelet 
ends (Italiano and Hartwig 2013). 
 
1.3.1.4 Regulation of platelet production 
 
Primary haemostasis requires an adequate circulating platelet mass (Kelley 
2013). Platelet mass is defined as the volume of blood that is comprised 
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solely of platelets (refer to Section 1.3.3.3). Platelet mass is an indirect 
measure of the number of available thrombopoietin (TPO) receptors. 
 
Platelet mass is maintained primarily by the TPO/TPO-receptor system 
(Kuter 1996, Kelley 2013). Thrombopoietin is a cytokine that is produced 
primarily by the liver and to a lesser degree the kidney (Boudreaux 2010b). 
Receptors are present on both megakaryocytes and platelets.  When TPO 
binds to megakaryocytes thrombopoiesis occurs; however when TPO binds 
to platelets, there is internal degradation of TPO which renders it unavailable 
for binding to megakaryocytes (Kuter 1996, Kelley 2013). In health, platelet 
numbers are maintained within a narrow range, with the majority of TPO 
degraded by platelets and low basal concentrations maintaining platelet 
production (Kuter 1996, Kelley 2013).  
 
With a decrease in platelet mass (which occurs with a decrease in the 
number of platelets or a decrease in the number/function of platelet TPO 
receptors), there is an increase in TPO concentration, with consequent 
megakaryocyte stimulation and enhanced thrombopoiesis (Kuter 1996, 
Kelley 2013). 
 
Assuming there is consistent TPO receptor density, the number of receptors 
on numerous small platelets is equivalent to the number of platelet receptors 
on lesser numbers of large platelets. Thus platelet mass (and the number of 
TPO receptors), and not platelet number determines platelet production 




1.3.2.1 Causes of true thrombocytopenia 
 
Thrombocytopenia, defined as a low number of platelets in the peripheral 
circulation, occurs with decreased or defective platelet production, increased 
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platelet consumption or loss, increased platelet destruction or abnormal 
distribution (sequestration) (as reviewed by Feldman et al., 2000).  
 
Decreased or defective platelet production may result from drug, chemical or 
toxin exposure causing cytotoxicity or an idiosyncratic reaction; irradiation 
causing cell death and bone marrow suppression; viral or rickettsial 
infections; myelophthisis due to neoplasia or fibrosis; myelonecrosis; or 
genetic β-tubulin defects (Boudreaux 2010b). Increased platelet consumption 
relates to activation of the coagulation system and may occur for example in 
disseminated intravascular coagulation. Increased platelet loss may result 
from extensive trauma or external haemorrhage (Boudreaux 2010b). 
Increased platelet destruction most commonly occurs due to immune-
mediated mechanisms. Immune-mediated destruction of platelets is primary 
(idiopathic) or secondary to infectious agents, neoplasia or drug 
administration (Boudreaux 2010b). Platelet sequestration occurs with 
diseases associated with splenomegaly or less commonly liver or bone 
marrow disease (Boudreaux 2010b). 
 
1.3.2.2 Causes of artefactual thrombocytopenia 
 
Inappropriate blood sample collection and handling techniques may induce in 
vitro platelet activation and platelet aggregation (Tvedten 2012). 
  
Artefactual platelet aggregation may result in uneven distribution of platelets 
within a blood sample, and pre-analytical error, with all platelet counting 
methodologies (manual counting, blood smear estimate and automated 
counting) (Tvedten 2012). An artefactual decrease in platelet count i.e. 








Platelet activation may also occur during sample collection due to: 
 blood sampling from small peripheral veins or veins with decreased 
blood flow  
 blood sampling using small-bore needles or excessive syringe 
pressure 
 excessive agitation of samples during mixing as opposed to gentle 
inversion 
 overfilling of blood collection tubes or inadequate sample mixing with 
anticoagulant 
 prolonged blood storage time (Pewarchuk et al. 1992).  
 
In addition, in vitro platelet aggregation occurs in certain individuals when 
blood contacts particular anticoagulants (Boudreaux 2010b). 
Ethylenediamine tetra-acetic acid (EDTA)-dependent 
pseudothrombocytopenia is well described in humans (Bizzaro 1995), with 
only rare (single case reports) in the dog (Wills and Wardrop 2008) , horse 
(Hinchcliff et al. 1993) and miniature pig (Ragan 1972). In people, EDTA-
induced pseudothrombocytopenia involves autoantibody-mediated 
agglutination of platelets (Casonato et al. 1994). EDTA induces calcium 
chelation and promotes a conformational change in GP IIb/IIIa on platelets, 
leading to exposure of a cryptic antigen with subsequent anti-platelet 
antibody binding and platelet aggregation (Casonato et al. 1994, Fiorin et al. 
1998).  
 
Traditionally, it was believed that platelet clumping rarely occurred with other 
anticoagulants, including citrate (Shreiner and Bell 1973, Onder et al. 1980, 
Payne 1985), however, results of more recent studies appear to contradict 
this assumption. Lower platelet counts (due to increased platelet 
aggregation) have been reported in citrated human blood samples compared 
to EDTA-anticoagulated samples (Macey et al. 1999, Ahnadi et al. 2003). 
Likewise, Stokol and Erb (2007) reported that the median platelet count in 50 
dogs with neoplasia was significantly lower in citrate- compared to EDTA-
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anticoagulated blood, due to platelet aggregation occurring more frequently 
in the samples containing citrate.  
 
1.3.2.3 Breed variation in platelet characteristics 
 
Certain dog breeds have platelet indices that commonly lie outside non-
breed specific reference intervals. In the CKCS, thrombocytopenia is 
common and is usually accompanied by macrothrombocytosis (Brown et al. 
1994).  A review of CKCS platelet characteristics is presented (refer to 
Section 1.3.7).  
 
Other breed specific platelet variations include mild thrombocytopenia in 
greyhounds (Santoro et al. 2007) and thrombocytopenia and 
macrothrombocytosis in the Norfolk terrier (Gelain et al. 2010). The cause of 
the greyhound and Norfolk terrier breed specific platelet variations is 
currently unknown. 
 
1.3.3 Methods of platelet enumeration 
 
There are four major laboratory methods of counting platelets: 1) manual 
methods using microscopy, 2) automated methods using commercial 
analysers including a) impedance analysis and b) optical light 
scatter/fluorescence analysis, 3) directly measured plateletcrit (PCT) (from 
which a platelet count is derived) (Tvedten et al. 2008, Tvedten et al. 2012) 
and 4) immunoplatelet counting by flow cytometry (Harrison and Briggs 
2013). 
 
1.3.3.1 Manual methods 
 
Manual methods of assessing platelet number are manual counting and 




Until recently, manual counting was considered the gold standard in people 
(Lancé et al. 2012). With this method, a glass counting chamber 
(haemocytometer) set on top of a microscope stage is used to count the 
number of platelets in a specific fluid volume (after the addition of 
erythrocyte-lysing agents), permitting calculation of the concentration of 
platelets in the fluid (Tvedten 2012). Manual counting however is laborious 
and subjective with a high degree of imprecision. Inter-observer coefficient of 
variation is typically reported to be approximately 10-25% (Harrison et al. 
2000, Briggs et al. 2007).  
 
The second manual method, blood smear estimation, involves estimation of 
platelet numbers during examination of a stained blood smear (Tvedten 
2012). Blood smear estimates, compared to manual counts, are obtained 
comparatively simply and quickly and provide a reasonable estimate of 
platelet numbers (Tvedten 2012).   
 
1.3.3.2 Automated methods 
 
Automated cell counting is based on either impedance or optical 




The impedance principle (or Coulter principle) transformed blood counting in 
the 1950s, and in the late 1970s impedance-based automated platelet 
counts became commercially available (Harrison and Briggs 2013). Today it 
remains a common method in many modern instruments but has largely 
been replaced by optical counters. 
 
According to the impedance principle, cells are passed through an aperture 
in an electrode in an electrically conducting fluid. The passage of a cell 
produces a change in electrical resistance, proportional to the size of the cell 
(Tvedten 2012). Cell number and size are determined by the frequency and 
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magnitude of change in resistance, respectively. Impedance counters are 
calibrated to count cells within an appropriate species specific size interval 
via adjustment of electronic thresholds (Tvedten 2012). The presence of 
larger platelets may lead to analytical inaccuracy because 
macrothrombocytes can be misclassified as erythrocytes (Moritz and Becker 
2010, Tvedten 2012). This is a recognised problem in the CKCS breed (refer 




Optical based cell counting methods were introduced in the 1970s (Lancé et 
al. 2012). Optical counters measure not only the size (volume) but also 
internal complexity of cells, based on assessment of light scatter at different 
angles (refractive index) or cell fluorescent intensity. This has reduced the 
analytical error associated with discrimination of cells based upon volume 
alone (Moritz and Becker 2010).  
 
Optical based haematology instruments used in referral veterinary 
laboratories include the Advia 120/2120 (Siemens Healthcare Diagnostics, 
Tarrytown, NY, USA) and Sysmex XT-2000iV (Sysmex Corporation, Kobe, 




The Advia 120/2120 uses the flow cytometer principle and contains a laser 
optical bench that consists of a flow cell, laser diode, and detector (Macey et 
al. 1999). The Advia 120/2120 differentiates platelets from other cells based 
on cell size (volume) and refractive index (density) (Macey et al. 1999).  
 
After dilution, blood cells are passed through a flow cell that is illuminated by 
a laser diode. The resultant light scatter signals are acquired at 2 different 
angles: 2-3° (low angle scatter) and 5-15° (high angle scatter) (Briggs et al. 
2007). These values are translated into volume and refractive indices by 
calculation, using the Mie theory of scattering of light (Brummitt and Barker 
21 
 
2000). Two light-scatter measurements are produced, and are displayed on 
a cytogram with platelets identified in the region corresponding to a volume 
of 1 to 60 fL and refractive index of 1.35 to 1.40. The platelet scatter 
cytogram (Figure 1.3) displays platelets with volumes of 0 fL to 20 fL and 
large platelets 21 to 30 fL, whereas the large platelet area of the red blood 
cell scatter cytogram (Figure 1.4) displays large platelets with volumes 
between 31 fL and 60 fL (Siemens 2002). The final platelet count is the sum 
of all platelets and large platelets, detected in the platelet and red blood cell 
scatter cytograms respectively (Briggs et al. 2007).  
 
Integrated analysis is used to assist discrimination of standard-sized 
platelets, large platelets, erythrocytes, erythrocyte fragments and erythrocyte 
ghosts (Brummitt and Barker 2000, Briggs et al. 2007). Erythrocyte 
fragments have a higher refractive index than platelets and as a result are 
located low and to the right of the graph, whereas red cell ghosts have a 
refractive index less than platelets and as a result are located above and to 
the left (Briggs et al. 2007).  
 









Figure 1.3: Platelet scatter cytogram. 
A graphical display of different light scatter signals with high-angle 
on the x axis, and the low-angle on the y axis. The platelet scatter 
cytogram depicts platelets (volumes of 0 fL to 20 fL), large 
platelets (21 to 30 fL), erythrocytes and erythrocyte ghosts and 















Figure 1.4: Red blood cell scatter cytogram. 
Area labelled area 3 depicts large platelets with volume 31 to 60 
fL. Area labelled 1 is the platelet scatter cytogram (refer to figure 




By contrast to the Advia 120/2120 which uses size (volume) and refractive 
index (density) to identify platelets, the Sysmex XT-2000iV uses size and 
nucleic acid staining (Tvedten 2012).  
 
The Sysmex XT-2000iV provides both an optical and an impedance platelet 
count (PLT-O and PLT-I respectively). The optical platelet count is obtained 
using the reticulocyte channel. Firstly, the RNA/DNA of platelet membranes 
and granules and reticulated cells are stained with a fluorescent dye 
(polymethine). Secondly, each cell is passed through the flow cell illuminated 
by a laser diode. The fluorescent intensity of each cell is determined, and 
permits the differentiation of platelets and large platelets from erythrocytes 
and reticulocytes (Tvedten 2012).  
 
The majority of large automated haematology analysers are developed for 
use in people, with species adaptation necessary for animal use (Moritz et al. 
2004). Species adaptation is achieved with software packages used to 
modify analyser settings (Moritz et al. 2004). Table 1.1 lists the platelet 
counting principle of some automated haematology instruments that have 
been assessed in the veterinary literature. 
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Manufacturer Instrument Platelet counting principle 






Optical (single scatter channel) 





(Tvedten et al., 2012; Kelley et 
al., 2014; Davies et al., 2008) 
Sysmex corporation Sysmex XT-2000iV Impedance and optical 
(Willard and Tvedten 2011) 
Abbott diagnostics Cell-Dyn 3500* 
 
*Later Cell-Dyn models 
including the Cell-Dyn 4000 
and Cell-Dyn Sapphire 
provide impedance, optical 
and immunological counts 
Impedance 
(Tvedten et al., 2008) 
 
 
Table 1.1: Summary of some of the automated haematology 
instruments assessed in the veterinary literature for their ability to 
discriminate platelets from other cells. 
 
1.3.3.3 Plateletcrit  
 
Platelet count can also be derived from PCT. Plateletcrit refers to the volume 
of blood that is comprised solely of platelets, and is reported as a percentage 
(Tvedten 2012). 
 
Importantly, PCT is the most physiologically relevant platelet parameter 
(Northern and Tvedten 1992, Butkiewicz et al. 2006) because platelet 
function depends on total platelet mass rather than platelet number 
(Thompson and Jakubowski 1988, Smedile et al. 1997). Plateletcrit is 
measured by two different methods, the direct method (from which a platelet 







With the direct method, the IDEXX VetAutoread Hematology analyser 
(IDEXX Laboratories, Westbrook, ME, USA) is used to perform a 
Quantitative Buffy Coat (QBC) analysis. Plateletcrit is measured directly from 
the width of the platelet layer in QBC tubes filled with blood and centrifuged 
(similar to the way in which haematocrit [HCT] is assessed). The 
VetAutoread converts the PCT to a platelet count (platelets/L), an index that 
is more familiar to clinicians. The actual method by which the VetAutoread 




The Advia 120/2120 reports a calculated PCT which is derived from the 
product of the platelet count and mean platelet volume [MPV] (Tvedten et al. 
2012). The PCT reported by the Advia 120/2120 is expressed as a 
percentage.  
 
The Sysmex XT-2000iV on the other hand, uses the impedance channel to 
determine MPV (and thus PCT), and is therefore unable to provide an 
accurate PCT in cases with macrothrombocytopenia (Lilliehöök and Tvedten 
2009). 
 
1.3.3.4 Immunoplatelet counting by flow cytometry 
 
Immunoplatelet counting by flow cytometry is the current platelet counting 
reference method for people (Harrison et al. 2000). With this method, 
monoclonal antibodies against specific platelet cell surface antigens are 
conjugated to a fluorophore and antigens are detected by their fluorescence 
as they pass through a flow cytometer (Harrison et al. 2000). This technique 




1.3.4 Additional platelet indices provided by the Advia 120/2120 
 
In addition to the commonly reported platelet count, the Advia 120/2120 
provides additional platelet indices including MPV, platelet volume 
distribution width (PDW), MPC concentration, PCDW, mean platelet mass 
(MPM), platelet mass distribution width (PMDW) and platelet clump and large 
platelet indices (Tvedten 2012). The meaning of these platelet indices are 
briefly described below and summarised in Table 1.2. 
 
Several of these indices have been proposed to be markers of platelet 
activation. During activation, platelets swell due to fluid uptake and 
degranulate (Macey et al. 1999) resulting in an increase in MPV and a 
decrease in MPC concentration and MPM (Park et al., 2002). This is 
accompanied by an increase in the distribution width of each index (PDW, 
PCDW and PMDW) (Chapman et al. 2003, Stokol and Erb 2007).  
 
 
Table 1.2: Major Advia 120/2120 platelet indices 
 
Platelet parameter Abbreviation Unit Description 
Platelet count PLT 10
9
/L Platelet count 
Plateletcrit PCT % Volume of blood comprised of 
platelets 
Mean Platelet Volume MPV fL Average platelet size 
Platelet Volume Distribution 
Width 
PDW % Indicator of the variation in platelet 
size 




g/L Measure for platelet refractive index, 
linearly related to platelet density 
Platelet Component 
Distribution Width 
PCDW g/L Indicator of the variation in platelet 
density 
Mean Platelet Mass MPM pg Measure for mass of platelet 
component 
Platelet Mass Distribution 
Width 
PMDW pg Indicator of the variation in platelet 
component mass 
Automated Platelet Clump 
Count  
APCC + (if APCC is > 300) Automated flag of platelet aggregates 
Large platelet LPLT + (%LPLT 10 to 11.9%) 
++ (%LPLT 12 to 14%) 
+++ (%LPLT > 14%) 
Platelets with a volume 21 to 60 fL 
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1.3.4.1 Mean platelet volume  
 
Mean platelet volume refers to the average volume of platelets (Bommer et 
al. 2008).  
 
An increase in platelet size may be real or artefactual: 
 
As summarised previously, an increase in MPV occurs with platelet 
activation (Park et al. 2002). However, MPV may increase for a variety of 
other reasons.  Unsurprisingly, breed-associated macrothombocytosisis is 
associated with an increased MPV (Tvedten et al. 2012). Additionally, an 
increased MPV occurs with accelerated thrombopoiesis (for example in 
cases with increased platelet consumption/loss or increased platelet 
destruction) (Brown et al. 1994, Wiwanitkit 2004, Boudreaux 2010b).  
 
Anticoagulant type, storage time, temperature and osmotic environment are 
also reported to affect platelet size and shape (Boudreaux 2010b). It has 
been suggested that only citrated canine blood samples are suitable for 
assessment of platelet size because platelets exposed to EDTA undergo an 
artefactual increase in size as assessed by light microscopy (Handagama et 
al. 1986). Although a later study in 69 healthy CKCS showed that 
macrothrombocytosis (defined as greater than 30% of platelets having a 
diameter of at least 3 μm on microscopic examination) was consistently 
identified in both EDTA and citrated samples of 22 dogs, agreement between 
MPV in both samples was not assessed (Cowan et al., 2004).  
 
1.3.4.2 Platelet volume distribution width  
 
Platelet volume distribution width provides an indicator of the variation in 
platelet size (Russell 2010).  In order to calculate the PDW, the SD of platelet 
volume is divided by the MPV and multiplied by 100 (Brummitt and Barker 
2000). In humans, PDW has been used to differentiate between destructive 
thrombocytopenia (immune-mediated thrombocytopenia) and hypoproductive 
thrombocytopenia (aplastic anaemia), for which there is an increase and 
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decrease in PDW respectively (Kaito et al. 2005). Despite the potential use 
of PDW and MPV in dogs, they are currently not routinely used in veterinary 
practice. Published reference intervals for PDW and MPV are available for 
dogs (Moritz et al. 2004), however due to the non-linear inverse relationship 
of these volume indices with platelet count, interpretation of changes in PDW 
and MPV requires consideration of an individual’s platelet count (Bommer et 
al. 2008).  
 
1.3.4.3 Mean platelet component concentration and platelet component 
distribution width  
 
Mean platelet component concentration is an automated platelet index, 
provided by the Advia 120/2120 (Macey et al. 1999). It is a measure of 
platelet refractive index, which is linearly related to platelet density, and 
inversely related to platelet activation (Ahnadi et al. 2004).  
 
Platelet component distribution width is an indicator of the variation in MPC 
concentration and PCDW is increased if both non-degranulated and 
degranulated circulating platelets are present. An increased PCDW is 
therefore an indirect marker of platelet activation (Moritz et al. 2005, 
Boudreaux 2010b).  
 
The calculation of MPC concentration is based upon the following formula: 
MPC concentration (g/dL) = (mean refractive index -1.333)/(0.0018/(g/dL)), 
where 1.333 = refractive index of water and 0.0018 (g/dL) = average 
refractive index increment (Chapman et al. 1998). The formula for PCDW is 
calculated as the SD of the platelet refractive index histogram (Siemens 
2002).  
 
Effects of factors other than platelet activation on MPC concentration have 
not been assessed in dogs. However, in one study involving 500 healthy 
people, MPC concentration increased from childhood (10-18 years) to adult 
age (18-45 years) and decreased thereafter (Giacomini et al. 2001). Macey 
et al. (1999) assessed changes in MPC concentration and P-selectin 
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expression in 20 human blood samples anticoagulated with EDTA, stored at 
room temperature, and assessed at timed intervals over a 3-hour period. The 
MPC concentration decreased and P-selectin expression increased over 
time. The relationship between age and MPC concentration, and the effect of 
storage time, in dogs is unknown.  
 
Mean platelet component concentration studies in people 
 
The MPC concentration has been used as an indicator of platelet activation 









Congestive heart failure 
(due to left ventricular 
systolic dysfunction) 
MPC concentration is lower in patients 
with congestive heart failure compared to 
healthy controls 
 
Sodium citrate; not 
recorded 




MPC concentration is lower in patients 
with acute myocardial infarction compared 
to patients with unstable angina  
EDTA; between 
30-240 minutes 
(Kennon et al. 
2003) 
Coronary disease MPC concentration is lower in patients 
with stable angina, unstable angina and 




(Pawlus et al. 
2010) 
Diabetes mellitus MPC concentration is lower in diabetes 
mellitus compared to healthy controls 
EDTA; within 60 
minutes 
(Bae et al. 
2003) 
Strenuous exercise 
(pre- and post-race 
sampling) 
Racing is associated with a decrease in 
MPC concentration 
EDTA; within 90 
minutes 
(Kratz et al. 
2006) 
Deep vein thrombosis 
 
MPC concentration is lower in patients 
with deep vein thrombosis compared to 
healthy controls  
EDTA; within 60 
minutes 
(Cay et al. 
2012) 




Clopidogrel therapy is associated with an 
increase in MPC concentration 
EDTA; within 60 
minutes 
(Ahnadi et al. 
2004) 
 
Table 1.3: Studies that have used MPC concentration as an 
indicator of platelet activation in people.  






Mean platelet component concentration studies in dogs 
 
The use of MPC concentration as an indicator of platelet activation in dogs 
has been reported in three studies to date: 
 
Two studies used MPC concentration to assess platelet activation after 
exercise. Moritz et al. (2003) reported a significant decrease in MPC 
concentration and increase in PCDW following short duration, strenuous, 
sled-pulling activity in 18 Siberian Huskies. By contrast, Bauer et al. (2012) 
reported no significant change in MPC concentration or PCDW following 
submaximal aerobic exercise in nine healthy beagles. These conflicting 
results may reflect differences in the type or duration of exercise, or be 
related to the smaller number of dogs (and lower power) in the latter study.  
  
Moritz et al. (2005) compared MPC concentration and P-selectin expression 
for the identification of platelet activation in 20 dogs with septic or non-septic 
inflammatory diseases. The proportion of dogs with decreased MPC 
concentration (16/20) was higher than the number of dogs with increased P-
selectin expression (13/20). Due to the lack of a gold standard, it was not 
known if MPC concentration was more sensitive or less specific compared to 
P-selectin expression as a marker of platelet activation. However, such 
conclusions must be interpreted with caution due to the low number of dogs 
in the latter study.  The PCDW was greater than the upper limit of the 
reference interval in 14 dogs.  
 
1.3.4.4 Mean platelet mass  
 
Mean platelet mass is a measure of the mass of platelet component 
excluding water (Zelmanovic 2006). A decrease in MPM would be expected 





Mean platelet mass is obtained using conversion of volume and refractive 
index by mathematical algorithm: 
MPM (in pg) = MPC concentration (in g/dL) x MPV (in fL) x 100 (Chapman et 
al. 1998). 
 
1.3.4.5 Platelet mass distribution width  
 
Platelet mass distribution width is an indicator of the variation in mass of 
platelet component excluding water.  
The formula for PMDW is calculated as the SD of the platelet mass 
histogram (Siemens 2002). 
 
1.3.4.6 Automated platelet clump count  
 
Assessment of platelet clumping may be subjective (examination of the 
frequency and degree of platelet aggregation at the blood smear feathered 
edge) or quantitative (using the Advia 120/2120 APCC index). 
 
The number of platelet clumps detected by the Advia 120/2120 corresponds 
to the number of events that fall within the platelet clump area, which 
originates from the noise cluster area in the peroxidase channel and extends 
to the right of the lymphocyte area (Siemens 2002, Stokol and Erb 2007). 
When the APCC is greater than 300, the Advia 120/2120 flags the sample by 
marking the platelet clumps index as ‘+’ (Siemens 2002). 
 
In a 2007 study that assessed APCC in dogs, the Advia 120/2120 flagged 
platelet clumps in 3 of 51 samples without visually detected clumps in 
smears (to provide a specificity of 94%) and failed to flag platelet clumps in 
44 of 49 samples in which large or frequent aggregates were detected 
visually (to provide a sensitivity of 10%) (Stokol and Erb 2007). The results of 
this latter study therefore suggest that APCC is poorly sensitive and highly 
specific at detecting platelet clumping and that APCC should not be used 
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independently to verify the presence or absence of platelet clumps (Stokol 
and Erb 2007).  
 
1.3.5 Assessing macrothrombocytosis 
 
In the majority of dog breeds, platelets are typically one quarter to half the 
size of an erythrocyte, and only occasionally larger than a red blood cell 
(Boudreaux 2010b). The term macrothrombocyte refers to a platelet of 
increased size; and macrothrombocytosis refers to the presence of increased 
numbers of large platelets in circulation (Bertazzolo et al. 2007). Assessment 
of macrothrombocytosis may be subjective or quantitative: 
 
 A platelet is subjectively defined as a macrothrombocyte if it is as 
large as or larger than a red blood cell (as assessed by light 
microscopy), and a diagnosis of macrothrombocytosis is made if more 
than 30% of platelets fulfil this criterion (Singh and Lamb 2005, Gelain 
et al. 2010).  
 
 Macrothrombocytosis can be quantitatively assessed using electron 
microscopy (Cowan et al. 2004). By this method, a platelet is defined 
as a macrothrombocyte if it has a diameter greater or equal to 3µm, 
and a diagnosis of macrothrombocytosis is made if more than 30% of 
platelets fulfil this criterion (Cowan et al. 2004).  
 
The number of macrothrombocytes may also be quantitatively assessed 
using an automated haematology instrument such as the Advia 120/2120 or 
Sysmex XT-2000iV. The Advia 120/2120 classifies platelets with a volume 
21 to 60 fL as large, and flags the presence of large platelets in the sample 
using the large platelet index when greater than or equal to 10% of the 
platelets fall within this range (Table 1.4) (Siemens 2002). The Advia 





Advia 120/2120 large platelet index severity 
level 
% Large platelets 
+ ≥ 10 to 11.9 
++ 12 to 14 
+++ > 14 
 
Table 1.4: Advia 120/2120 large platelet index severity level - 
percentage of large platelets in each category 
 
The Sysmex XT-2000iV has also been used to determine macrothrombocyte 
count. In one study utilising the Sysmex XT-2000iV, a PLT-O cytogram was 
regated with a subjective algorithm based on the appearance of the PLT-O 
cytograms from dogs without large platelets, and this algorithm was then 
applied to all original PLT-O counts. The reported number of large platelets 
per sample was the difference between the original PLT-O count and the 
regated optical count (with the latter representing the number of normal sized 
platelets) (Tvedten et al. 2008). 
 
1.3.6 Analysis of platelet function 
   
The following tests of platelet function are based on different biologic 
principles, 1) platelet aggregometry, 2) CT, 3) thromboelastography and 4) 
platelet activation markers: 
 
1.3.6.1 Platelet aggregometry; a low shear assay 
 
Platelet aggregometry involves the assessment of platelet aggregation after 
exposure to certain agonists and provides an assessment of platelet function 
(Tvedten 2012). There is no standardised method for assessing platelet 
aggregation in dogs, with test procedures and aggregating substances 






Optical (turbidometric) aggregometry 
 
Optical aggregometry was introduced in the 1960s (Carr Jr 1997). Using this 
method, agonists are added to platelet-rich plasma to cause platelet 
aggregation (Jandrey 2012). As aggregation progresses the platelet-rich 
suspension clears, resulting in increased light transmission (Jandrey 2012). 
This alteration in light intensity is detected by a spectrophotometer and 
recorded digitally or by chart recorder. Results are reported as the 
percentage increase in light transmission relative to the pre-agonist baseline 
aggregation (Dosh and Steinhubl 2010). Disadvantages of this method are 
that platelets aggregate under low shear stress conditions and that the 
absence of other cellular elements (such as red and white blood cells) may 
result in suboptimal mimicry of in vivo platelet aggregation (Dosh and 
Steinhubl 2010). In addition, the need for centrifugation to create the platelet-
rich plasma may predispose to platelet aggregation prior to analysis (Jandrey 
2012). Despite these problems, optical aggregometry has been widely used 
in veterinary science (including CKCS platelet aggregation studies, refer to 
Section 1.4.1.1). 
 
Whole blood impedance aggregometry 
 
The technique of whole blood impedance aggregometry, introduced in the 
1980s, may avoid some sample preparation issues associated with optical 
aggregometry (Jandrey 2012). Additionally, due to the use of whole blood, 
impedance aggregometry may be more physiologically appropriate than 
optical aggregometry (Jandrey 2012). With this technique two electrodes are 
placed in a sample containing anticoagulated whole blood and electrical 
impedance is assessed pre- and post- addition of a platelet agonist. During 
aggregation, platelets form a monolayer on electrodes and change (increase) 
the impedance of an electrical current (Jandrey 2012).  The degree of 
aggregation is thus assessed as the increase in electrical impedance 




1.3.6.2 Platelet function analyser; a high shear assay 
 
The platelet function analyser (PFA-100, Siemens Healthcare Diagnostics 
Product GmbH, Marburg, Germany), is a point of care, bench-top platelet 
function analyser developed for use in people and validated for use in dogs 
(Mischke and Keidel 2002). The PFA-100 is a sensitive screening tool for 
general defects in primary haemostasis (Clancey et al. 2009a). 
 
The PFA-100 evaluates both platelet adhesion and aggregation by 
simulating high-shear blood flow at a site of endothelial damage (Callan and 
Giger 2001). This is achieved by rapid in vitro flow of a citrated whole blood 
sample through an aperture in a disposable collagen-coated membrane 
containing ADP or epinephrine (Tvedten 2012). The high shear blood flow 
causes platelet activation and adhesion to the membrane, mediated primarily 
by VWF (Tarnow and Kristensen 2010). The subsequent release of platelet 
granules and presence of agonist causes platelet aggregation via GP IIb-IIIa 
(Tarnow and Kristensen 2010). The time it takes for a platelet plug to form 
and occlude blood flow through the membrane aperture is measured in 
seconds and is called the CT (Tarnow and Kristensen 2010) (Figure 1.5). 
Epinephrine does not consistently cause platelet aggregation in dogs and 
collagen-epinephrine cartridges are therefore considered to be less accurate 
in the dog, and the use of collagen-ADP cartridges are more commonly 
























Figure 1.5: Cross-sectional diagram of the Platelet Function 
Analyser  
(PFA-100) instrument (Siemens Healthcare Diagnostics Product 
GmbH, Marburg, Germany). 
Blood is passed rapidly through an aperture in an agonist 
containing collagen-coated membrane to mimic in vivo platelet 
adhesion and activation. The time is takes for a platelet plug to 
form and occlude blood flow is the closure time (adapted from 
Jandrey 2012). 
 
The PFA-100 CT is sensitive to platelet function, platelet number, HCT and 
drug therapy: 
 
In the absence of macrothrombocytosis, there is an inverse relationship 
between CT and platelet count less than 150 x 109/L (Mischke and Keidel 
2003). 
 
Additionally in dogs there is an inverse relationship between CT and HCT 
(Mischke and Keidel 2003). Reasons for the latter include increased blood 
flow (associated with decreased blood viscosity) and altered blood cell 
distribution (more central flow of platelets within in vivo and in vitro 
capillaries) with lower HCT values (Mischke and Keidel 2003). One study 
investigated the change in CT (using collagen-ADP cartridges) following 
haemodilution of whole blood samples using fresh autologous platelet-rich 
plasma. The initial samples with HCT 0.39-0.54 L/L produced a mean CT +/- 
SD of 57.8 +/- 5.75 seconds, whereas the haemodiluted samples, with HCT 
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of 0.33 and 0.27 L/L, produced significantly prolonged CT of 61.1 +/- 4.64 
seconds and 64.3 +/- 6.79 seconds respectively. Overall, an increase in CT 
has been demonstrated in dogs with a HCT less than 30-40% (Callan and 
Giger 2001, Mischke and Keidel 2003, Clancey et al. 2009b).  
  
Furthermore, non steroidal anti-inflammatory drug administration (specifically 
aspirin and ketoprofen therapy) has been shown to increase CT in dogs 
when collagen-ADP and/or collagen-epinephrine cartridges are used (Keidel 





Thromboelastography was introduced in the late 1940s (Hartert 1948, 1951). 
Thromboelastography assesses the changes in viscoelastic properties of 
whole blood during clot formation under low shear conditions (Kol and 
Borjesson 2010). The use of whole blood permits assessment of the 
influence of circulating plasma and cellular components on platelet function 
and clot formation. Thromboelastography therefore may more accurately 
reflect in vivo haemostasis and more efficiently predict haemostatic kinetics 
compared to routine plasma-based assays (Hoffman 2001). 
 
Thromboelastography measurements include reaction time, kinetics, 
maximum amplitude and alpha angle which provide an indicator of the time 
to initial fibrin formation, speed of clot formation, speed of clot strengthening 
and clot strength respectively (Jandrey 2012). 
 
1.3.6.4 Platelet activation markers 
 
Platelet activation markers are available and used in humans, infrequently 
utilised in animals and potentially useful for application to veterinary studies 
(refer to Section 1.4.1.4). Platelet activation markers may be classified as 
direct (platelet surface-associated P-selectin expression and BTG and PF4 
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plasma concentrations) and indirect (soluble P-selectin and thromboxane B2 
plasma concentrations).   
 
In addition, as previously discussed (in Section 1.3.4), several of the Advia 
120/2120 derived platelet indices, including MPV, MPC concentration and 
MPM (and their respective distribution widths PDW, PCDW and PMDW) are 
also (direct) markers of platelet activation. 
 
Platelet surface P-selectin expression  
 
Platelet activation results in degranulation and release of proteins such as P-
selectin, which are subsequently transported to the cell membrane. This 
causes a change in the number of cell surface molecules on circulating 
platelets, which may be measured by immunofluorescent flow cytometry 
(Macey et al. 1999, Moritz et al. 2005): 
 
In short, platelets are marked with fluorescence-conjugated antibodies 
against activation-dependent markers such as P-selectin and passed 
through a flow cytometer (Zelmanovic and Hetherington 1998). The number 
of positive events determines the number of activated platelets and the 
degree of fluorescence relates to the number of activation dependent 
markers on each platelet (Zelmanovic and Hetherington 1998). 
 
Immunofluorescent flow cytometry is reported as sensitive and specific 
(Zelmanovic and Hetherington 1998, Ahnadi et al. 2004). However, the 
sensitivity of the test has been questioned relative to MPC concentration 
(Moritz et al. 2005).  Disadvantages of P-selectin expression assessment 
include expense and prolonged sample preparation time (approximately 60 










Soluble P-selectin is the soluble circulating isoform of P-selectin, which is 
detectable in blood by enzyme-linked immunosorbent assay (ELISA) 
methods (Blann et al. 2003).  Soluble P-selectin concentration is a less 
established marker of platelet activation compared to platelet bound P-
selectin.  
 
Platelet specific granular proteins i.e. β-thromboglobulin and platelet 
factor 4  
 
Platelet alpha granules contain a variety of proteins including BTG and PF4 
(Kamath et al. 2001). Both BTG and PF4 are specific to platelets, found in 
similar quantities within alpha granules and are released during platelet 
activation (Kamath et al. 2001). Therefore increased plasma concentrations 
are associated with increased in vivo platelet activation (Kamath et al. 2001). 
Detection of BTG and PF4 is achieved using an ELISA or radioimmunoassay 
(Kamath et al. 2001). 
 
Plasma metabolite thromboxane B2  
 
Plasma thromboxane B2 is the stable, inactive metabolite of plasma 
thromboxane A2. Plasma thromboxane A2 is generated by platelets from 
arachidonic acid in response to platelet agonist stimulation (Boudreaux and 
Catalfamo 2010). Generation of thromboxane A2 causes platelet aggregation 
and release of dense granule contents (Boudreaux and Catalfamo 2010). 
Measurement of plasma thromboxane B2 concentrations, via 
radioimmunoassay or ELISA, are reported methods of assessing platelet 
activation (Fuse and Kamiya 1994, Tarnow et al. 2005, Nielsen et al. 2007). 
 
Mean platelet component concentration  




1.3.7 Platelet evaluation and variation in the Cavalier King 
Charles spaniel 
 
Cavalier King Charles spaniels have a high prevalence of inherited, 
subclinical thrombocytopenia and macrothrombocytosis (Eksell et al. 1994, 
Pedersen et al. 2002, Cowan et al. 2004, Singh and Lamb 2005). These 
conditions have posed several unique challenges with regard to accurate 
enumeration of platelet numbers, and evaluation of their function, in this very 
popular breed.  The relevant literature pertaining to these issues is presented 
in the following pages, starting first with a review of the counting and 
evaluation methods, and followed by a review of the disorder itself. 
 
1.3.7.1 Platelet evaluation in the Cavalier King Charles spaniel 
 
1.3.7.1.1 Manual methods 
 
Prior to the availability of modern optical haematology instruments, manual 
methods of platelet counting were preferred for the CKCS breed because of 
the relative inability of impedance haematology instruments to distinguish 
large platelets from red blood cells (Brown et al. 1994, Eksell et al. 1994).  
 
One study in CKCS (Singh and Lamb 2005) reported that there was no 
statistically significant difference in platelet counts obtained by manual 
counting and blood smear estimation, however Olsen et al. (2004) reported 
that at lower platelet counts (less than or equal to 100 x 109/L), blood smear 
estimation underestimated platelet counts compared with manual counting, 
and theorised that this could be due to large platelets localising in the 
feathered edge of the blood smear. Furthermore, a later study by Tvedten et 
al. (2008) supported this theory, reporting that CKCS with greater than 50% 
macrothrombocytes (n=6) and CKCS with less than 50% macrothrombocytes 
(n=16) had 7.1 times and 2.4 times the number of platelets at the feathered 




1.3.7.1.2 Automated cell counting 
 
Impedance 
The majority of platelet studies in the CKCS breed (n=6) have utilised 
impedance based instruments due to the unavailability, until recently, of 
optical based instruments. Five of these studies reported that impedance 
counters underestimated platelet count compared to manual methods 
(manual counting or blood smear estimation), due to an inability to 
consistently distinguish large platelets from erythrocytes (Eksell et al. 1994, 
Olsen et al. 2001, Olsen et al. 2004, Bertazzolo et al. 2007, Tvedten et al. 
2008). The sixth study found no statistically significant difference between 
manual counting, blood smear estimation or impedance based counting and 
concluded that automated or blood smear estimates are sufficient to count 
platelets (Singh and Lamb 2005).  
 
Optical 
Five studies have utilised optical haematology analysers in the evaluation of 
platelet indices in the CKCS.  
 
The first of these assessed one of the earliest optical haematology 
instruments, the Technicon H1 (Technicon Instruments Corporation, Tarry 
Town, NY; now Siemens), precursor of the Advia 120 (Bertazzolo et al. 
2007). The latter study reported strong correlation between platelet counts 
obtained by the Technicon H1 and an impedance counter (Hemat 8, SEAC, 
Florence, Italy) and blood smear estimation. There was however poor 
agreement between the Technicon H1 and the Hemat 8 and blood smear 
estimation. This poor agreement was proposed to be due to inaccurate 
classification of large platelets as erythrocytes (Bertazzolo et al. 2007). 
 
The second study compared optical (Sysmex XT-2000iV PLT-O), impedance 
(Sysmex PLT-I and Cell-Dyn 3500), manual, and QBC plateletcrit-derived 
platelet counts (Figure 1.6). When platelet counts were greater than 164 x 
109/L (i.e. cases not likely to have macrothrombocytosis) all methods 
(excluding QBC plateletcrit platelet count) provided similar counts.  At lower 
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counts however, the differences between methods were greater. Overall, 
both optically and manually obtained platelet counts underestimated platelet 
numbers at lower counts, compared to the QBC plateletcrit, but performed 
better than impedance methods in these circumstances (Tvedten et al., 
2008). The latter study contested the traditional belief that manual counting is 












Figure 1.6: Optical (PLT-O), impedance (PLT-I and CELL-DYN), 
manual and QBC plateletcrit platelet counts in 27 CKCS. 
Figure reproduced from Tvedten et al. (2008). At lower platelet 
counts, PLT-O and manual counting performed better than PLT-I 
and Cell-Dyn, consistent with the improved ability of optical 
haematology instruments (such as the Sysmex XT-2000iV), to 
discriminate large platelets compared to impedance ones.  
 
The third study to use an optical haematology analyser in the evaluation of 
platelet indices in the CKCS,  reported an association between β1-tubulin 
mutation and macrothrombocytopenia and used the Advia 120 to obtain 
platelet counts (Davis et al. 2008) (refer to Section 1.3.7.2.3). 
 
A fourth study assessed the validity of the Advia 2120 generated PCT by 
comparing it to the QBC derived platelet count (the gold standard for platelet 
mass, Section 1.3.3.3) (Tvedten et al. 2012). To enable direct study 
comparisons, units of the Advia 120 PCT (%) were converted to units of the 
QBC derived platelet count (x10/L9) by multiplication of an estimated 
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conversion factor (i.e. 1000) (Tvedten et al. 2012). Bland Altman analysis 
showed fair agreement between the Advia 2120 PCT (x1000) and the QBC 
derived platelet counts, but the former had a negative bias  of 26 x 109/L, 
with underestimation of PCT particularly at lower PCT values (Tvedten et al. 
2012). The 95% limits of agreement were -149 to 97 x 109/L. 
 
Lastly, a recent CKCS study used both the Advia 120 and 2120 to determine 
platelet counts and PCT, and concluded that the use of PCT (as determined 
by the Advia 120/2120), compared to platelet count, avoided overestimation 




The PCT, derived from QBC analysis, is considered to be the gold standard 
for evaluating platelet mass in the CKCS (and other dogs with 
macrothrombocytosis) (Tvedten et al. 2012). In CKCS, the PCT is typically 
within reference intervals regardless of platelet count (Bertazzolo et al. 2007, 
Tvedten et al. 2012). Plateletcrit is therefore of value in these dogs to enable 
differentiation between inherited macrothrombocytopenia (PCT within 
reference intervals) and clinically relevant thrombocytopenia (decreased 
PCT) (Tvedten et al. 2008). A PCT reference interval for CKCS has not been 
established; however, Tvedten et al. (2012) reported a mean PCT and 95% 
confidence interval (for 31 clinically healthy CKCS) as 0.27% and 0.1-0.44% 
respectively (Tvedten et al. 2012). 
 
1.3.7.1.4 Mean platelet volume 
 
In the CKCS there is an inverse relationship between platelet size and 
platelet count. More specifically dogs with larger platelets have lower platelet 
counts (Brown et al. 1994, Cowan et al. 2004, Olsen et al. 2004, Singh and 
Lamb 2005).  
 
One CKCS study assessed MPV generated by the impedance haematology 
instrument Hemat 8 (SEAC, Florence, Italy) and did not find a significant 
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difference in CKCS with or without macrothrombocytes (11.6 and 12.1 fL 
respectively) (Bertazzolo et al. 2007). The same study also assessed the 
laser cell counter, Technicon H1, and reported that the MPV with or without 
macrothrombocytes was 5.2 and 6.6 fL respectively, approximately only half 
that obtained from the impedance instrument. This suggests that both 
instruments (impedance and older optical) are inaccurate in breeds with 
macrothrombocytosis due to an inability to detect large platelets (Bertazzolo 
et al. 2007). However another method to classify the presence or absence of 
macrothrombocytes was not used. 
 




The majority of platelet studies in the CKCS have defined thrombocytopenia 
as a platelet count less than 100x 109/L. This reference interval was 
originally selected to stringently define dogs with thrombocytopenia (Eksell et 
al. 1994, Pedersen et al. 2002). Using this definition, the reported 
prevalences of thrombocytopenia arising from various studies in the CKCS 
are 32/102 (31%) (Eksell et al. 1994), 9/17 (53%) (Olsen et al. 2001), 59/106 
(56%) (Pedersen et al. 2002), 36/69 (51%) (Cowan et al. 2004), 15/43 (35%) 
(Olsen et al. 2004) and 83/152 (55%) (Singh and Lamb 2005), based on 
manual platelet counts obtained using a haemocytometer. A further study 
assessing platelet number with blood smear estimation (as opposed to 
manual counting) reported a slightly lower prevalence of thrombocytopenia of 
9/41 (22%) (Bertazzolo et al. 2007). 
 
Despite these studies, the prevalence of thrombocytopenia in the CKCS, as 
assessed by a modern optical automated haematology instrument, has not 
previously been reported. However in two CKCS studies utilising the Sysmex 
XT-2000iV and Advia 2120, prevalences (using a definition of 
thrombocytopenia as a platelet count less than 100 x 109/L) can be 
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estimated from the graphs to be (10/27) 37% and (19/43) 44% respectively 
(Tvedten et al. 2008, Tvedten et al. 2012). 
 
The majority of studies reporting the frequency of thrombocytopenia in the 
CKCS originate from northern Europe (and in particular Denmark and 
Sweden); with only one Australian study to date (Singh and Lamb 2005). The 
latter study defined the lower limit of the reference interval for platelet count 
as  200 x 109/L because this was the limit used by common references 
(Barger 2003, Boudreaux 2010b) and commercial laboratories, and set by 
their impedance auto analyser. The latter study reported the frequency of 
thrombocytopenia as 90% with 25% of cases having severe 
thrombocytopenia (platelets less than 50 x 109/L). If however, the same the 
lower limit of 100 x 109/L was used, the frequency of thrombocytopenia, as 
reported above, was 55% (Singh and Lamb 2005) which is similar to the 
prevalence of thrombocytopenia found in CKCS residing in Denmark and 
Sweden (Pedersen et al., 2002, Eksell et al., 2004., Olsen et al., 2001, 
2004). 
 
Thrombocytopenia in the CKCS is typically mild-moderate. The range of the 
mean and median platelet counts from CKCS platelet studies (Table 1.5) are 
87.5-178 x 109/L and 92-238 x 109/L respectively, with an overall range of 



























































































































A study assessed 14 CKCS with a variety of diseases and found that more 
than 30% of platelets were larger in diameter (greater than 3.7µm) than 
platelets from healthy dogs of other breeds (Holme et al. 1981). Brown et al. 
(1994) subsequently investigated platelet size in 10 healthy CKCS, reporting 
a significantly larger platelet diameter in the CKCS compared to healthy dogs 
of other breeds, with median values of 2.5 to 3.75µm and 1.25 to 2.5µm 
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respectively. Platelet diameter in the CKCS showed bimodal distribution with 
44.5% platelets ranging in size from 1.25 to 2.5µm and 30% from 3.75 to 
5.0µm (Brown et al. 1994). Both studies used an eyepiece graticle to 
estimate platelet diameter. 
 
Approximately one-third of CKCS appear to have macrothrombocytosis, as 
reported in two studies totalling 219 individuals; 46/152 (30%) (Singh and 




Macrothrombocytopenia is defined as macrothrombocytosis and 
thrombocytopenia occurring together. 
 
The CKCS breed has a high prevalence of macrothrombocytopenia 
(Pedersen et al. 2002). Several studies suggest that approximately half of all 
CKCS have platelet variations without bleeding tendencies, characterised by 
the presence of thrombocytopenia – as assessed by manual count – in 31-
56% of dogs (Eksell et al. 1994, Olsen et al. 2001, Pedersen et al. 2002, 
Cowan et al. 2004, Olsen et al. 2004, Singh and Lamb 2005), and 
macrothrombocytosis affecting an overlapping 30-33% of dogs (Singh and 
Lamb 2005). 
 
The majority of CKCS with inherited platelet variation have 
macrothrombocytopenia (i.e. macrothrombocytosis is seen most often in 
combination with thrombocytopenia). The first CKCS study to demonstrate 
this graphically, by plotting MPV against platelet count, was published in 
2012 (Tvedten et al. 2012). No automated haematology instrument, prior to 
the Advia 120 has reportedly produced a reliable MPV in the CKCS. 
Macrothrombocytosis or thrombocytopenia alone appears to be an 
uncommon finding.  
 
In one study, 70% of CKCS with macrothrombocytosis had a platelet count 
less than 100x 109/L (Singh and Lamb 2005). Another study in CKCS 
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reported a significantly lower platelet count (median 63.5 x 109/L) in cases 
with macrothrombocytosis, compared to those with platelet size within 
reference interval (median 118 x 109/L; Mann-Whitney U = 290, p = 0.011) 
(Cowan et al. 2004). In the latter study however, there was some variability 
as to whether thrombocytopenia only 20/43 (47%), macrothrombocytes only 
8/43 (18%) or both conditions were present 15/43 (35%) (Cowan et al. 2004). 
 
The subclinical nature of macrothrombocytopenia in the CKCS is consistent 
with adequate platelet function, and is likely reflects the greater functional 
activity of macrothrombocytes (Smedile et al. 1997). 
 
Macrothrombocytopenia exhibits an autosomal recessive pattern of 
Mendelian inheritance (Pedersen et al. 2002, Singh and Lamb 2005). Singh 
and Lamb (2005) demonstrated an equal prevalence in both sexes, 
generation trait skipping, that parents of affected dogs were often related and 
that all progeny from two affected parents would be affected. The latter study 
also reported a high prevalence of affected dogs (90%), consistent with low 
numbers of non-carriers (Singh and Lamb 2005). 
 
The autosomal recessive nature of macrothrombocytopenia in the CKCS 
was confirmed by the identification of a mis-sense mutation at coding 
nucleotide 745 in the gene encoding β1-tubulin (Davis et al. 2008). The 
mutation results in the substitution of asparagine for aspartic acid at amino 
acid position 249. The latter forms part of the microtubule intraprotofilament 
binding site and the net result is impaired microtubule assembly (unstable α-
β tubulin dimers within microtubule protofilaments). Impaired microtubule 
assembly leads to altered proplatelet formation and release by 
megakaryocytes and results in macrothrombocytopenia (Davis et al. 2008). 
The lack of bleeding diathesis in macrothrombocytopenic CKCS suggests 
that the microtubule defect does not alter platelet function significantly (Davis 
et al. 2008). Additionally, preservation of an adequate platelet mass is likely 
responsible for maintenance of platelet function in macrothrombocytopenic 




The prevalence of the mutation is high in the United States with an estimated 
92% of CKCS either homozygous or heterozygous for the mutation (Davis et 
al. 2008). In contrast, in Ireland, 65% of CKCS were reportedly homozygous 
or heterozygous for the mutation (Davis et al. 2008). Platelet numbers were 
significantly different among groups based on the presence or absence of 
the β1-tubulin gene mutation; with low platelet counts (generally less than 
100 x 109/L), intermediate platelet counts (approximately 200 x 109/L) and 
higher platelet counts (typically greater than 250 x 109/L) correlated with a 
homozygous, heterozygous and clear state for the mutation respectively 
(Davis et al. 2008). There are currently no reports of the prevalence of the 
mutation in other parts of the world. 
 
Older studies have reported the β-1 tubulin isotype to be megakaryocyte-
specific (Schwer et al. 2001). In contrast, a more recent study which 
investigated the distribution of β-tubulin isotypes in human tissue reported β-
1 tubulin to be relatively ubiquitous, with highest expression in the heart, 
brain, ovary and thymus (Leandro‐García et al. 2010).  
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1.4 Valvular heart disease and platelet function in people 
and dogs 
 
In all species, valvular heart disease has the potential to affect platelet 
activation or function (Goldsmith et al. 2000). Resultant turbulent high-
velocity blood flow and fluid shear stresses may decrease platelet function 
via increased fragmentation of circulating VWF high molecular weight 
multimers (Tarnow et al. 2004) or increase platelet activation following 
damage to the vascular endothelium and cellular components of blood 
(Brown et al. 1975, Stein and Sabbah 1976, Goldsmith et al. 2000). The 
associations between valvular heart disease and platelet activation or 
function are not well understood, with conflicting results reported in the 
human and veterinary literature.  
 
In people, many studies have reported increased platelet activation in heart 
failure. However, only small numbers have specifically assessed platelet 
function in people with valvular disease (such as MVP) and many include 
patients receiving drug therapies with the potential to alter platelet function 
(Chung and Lip 2006). In addition, it is often unclear if cases are subclinical 
or clinical, preventing assessment of the association of platelet function with 
varying severities of heart disease.  
 
Multiple studies in dogs have assessed platelet function exclusively in 
patients with valvular disease (i.e. CVHD), using numerous methods 
including aggregometry, PFA-100 testing and thromboelastography; however 
in contrast to the medical literature, few veterinary studies have used platelet 
activation markers for this purpose.  Unlike their medical counterparts, the 
majority of canine studies excluded cases receiving drug therapies and 
included only subclinical CVHD cases (as reviewed by Tanaka and Yamane, 
2000).  
 
This section of this thesis will review platelet function in dogs with CVHD as 
assessed by platelet aggregometry, PFA-100 CT and thromboelastography, 
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followed by a review of the relatively small number of studies available on 
platelet activation markers in dogs with CVHD and the comparatively larger 
numbers of studies reporting platelet activation markers in people with 
valvular heart disease (including MVP). 
 
1.4.1 Platelet function and associations with chronic valvular 
heart disease 
 
1.4.1.1 Platelet aggregometry 
 
Most of the published aggregometry-based studies in CKCS have 
demonstrated an increased platelet aggregation response with varying 
degrees of severity of subclinical CVHD (regardless of MVR status), 
suggesting increased platelet reactivity (Olsen et al. 2001, Tarnow et al. 
2005, Nielsen et al. 2007). In one of these studies the increased aggregation 
response was found to be dependent on a platelet count greater than or 
equal to 100 x 109/L (Olsen et al. 2001) (Table 1.6). However, other studies 
reported decreased platelet aggregation in various dog breeds with clinical 
CVHD (Tanaka and Yamane 2000) and in CKCS with varying degrees of 
severity of subclinical CVHD (Cowan et al. 2004). It was suggested that this 
decreased platelet aggregation could be due to chronic platelet activation 
and subsequent platelet exhaustion (Tanaka and Yamane 2000) (Table 1.6). 
The latter authors reported that the concentrations of ADP that produced 
50% of the irreversible maximum aggregation (the enhancement of platelet 
sensitivity concentration) were significantly higher in New York Heart 
Association (NYHA) class III-IV (n=20) compared to class I-II cases (n=12), 
consistent with decreased platelet aggregation in more advanced/clinical 
CVHD cases. However, 9/32 (28%) of dogs were receiving angiotensin 
converting-enzyme blocker therapy, and the latter has been reported in the 
human literature to inhibit platelet activation (albeit inconsistently) (Chung 




Contradictory aggregometry results may reflect differences in the severity of 
heart disease between the study populations, although the lack of 
association between platelet aggregation response and CVHD severity in 
studies by Olsen et al. (2001) and Tarnow et al. (2005) is not highly 
supportive of this theory.  Alternatively the differences may reflect the 
different methodologies used (optical versus whole blood impedance 
aggregometry), or represent a lack of standardisation in canine platelet 
aggregation studies (Cowan et al. 2004, Tarnow et al. 2005).  
 




Platelet aggregation within 
reference interval 
Conditions 10 CKCS with varying degrees 
of severity of subclinical CVHD 
and platelets ≥ 100 x 10
9
/L, 
compared with control dogs and 
CKCS with platelets < 
100x10
9
/L (Olsen et al. 2001) 
 
31 CKCS with varying degrees 
of severity of subclinical CVHD 
and platelets ≥ 100 x 10
9
/L, 
compared with control dogs 




excluded from the study) 
 
12 CKCS with mild MVP and 
regurgitant jet size ≤ 20% 
(Nielsen et al. 2007) compared 
to control dogs. (Dogs with 
regurgitant jet size > 20% were 
excluded from the study). 
69 CKCS with varying degrees 
of severity of subclinical CVHD, 
compared to control dogs and 
regardless of platelet count 
(Cowan et al. 2004) 
 
 
32 dogs (various breeds) with 
symptomatic CVHD (New York 
Heart Association class III or IV 
cases), compared to control 
dogs (Tanaka and Yamane 
2000) 
 9 CKCS with varying degrees 
of severity of subclinical CVHD 
and platelets < 100 x 10
9
/L 
(Olsen et al. 2001) 
 
Table 1.6: Summary of the results of platelet aggregation studies 
in dogs with CVHD. 
 
1.4.1.2 Platelet function analyser closure times 
 
Platelet function analyser (PFA-100)-based studies have consistently 
reported increased CT in CKCS with mild-marked subclinical CVHD 
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suggesting decreased platelet function in such cases (Tarnow et al. 2003, 
Tarnow et al. 2005) (Tables 1.7 & 1.8 respectively). However, unlike 
aggregometry-based tests, CT was affected by quantitative and qualitative 
changes in circulating VWF (Tarnow et al. 2005).   
 
Continuous high shear stress from turbulent blood flow (associated with 
valvular regurgitation) results in increased fragmentation of circulating VWF 
high molecular weight multimers due to proteolysis of VWF (by the plasma 
metalloprotease, ADAMTS13, that cleaves VWF under high shear stress) 
(Tarnow et al. 2004). Therefore, the described increase in closure time likely 
reflects an alteration in VWF rather than a change in intrinsic platelet function 
(Tarnow et al. 2005). A decrease in VWF high molecular multimers is likely to 
be inversely proportional to increasing shear force because of the positive 
association between closure time and the degree of valvular regurgitation 
(Tarnow et al. 2003). Platelet aggregation at high shear rates is reliant on 
circulating VWF (Tarnow et al. 2005). Therefore, in vitro platelet function 
assays based on physiologic high shear rates and adhesion to a contact 
surface (e.g. PFA-100) will detect platelet dysfunction if a qualitative VWF 
defect is present; whereas low shear tests such as platelet aggregometry will 
be unaffected (Tarnow et al. 2005).  
 
The form of turbulent blood flow does not appear to be an important factor in 
platelet hypofunction (as assessed by CT), nor is it thought to be breed 
specific (Clancey et al. 2009a). Other studies have demonstrated increased 
closure times in a variety of dog breeds with various cardiac diseases 
including subaortic stenosis (Tarnow et al. 2005, Clancey et al. 2009a, 










 Control mixed breed  
Absent or minimal 
MVR (n=15) 
(Jet size ≤ 10%) 
Control CKCS 
Absent or minimal 
MVR (n=53) 












62 (55-66) 55 (52-64) 75 (60-84) * 87 (66-102) ** 
 
Table 1.7: Closure times (using collagen/adenosine diphosphate 
cartridges) with varying degrees of subclinical mitral regurgitation 
as assessed by the mitral regurgitant jet size (From Tarnow et al., 
2003).  
Data reported as median and 25th-75th percentiles. Results are 
different from the control CKCS at * p < 0.01 and ** p <0.0001. 
 
 Control mixed breed  
Absent or minimal  
MVR (n=14) 
(Jet size ≤ 10%) 
Control CKCS 
Absent or minimal  
MVR (n=14) 









62 (58-68) 64 (57-84) 106 (94-114) ** 
 
Table 1.8: Closure times (using collagen/adenosine diphosphate 
cartridges) with varying degrees of subclinical mitral regurgitation as 
assessed by the mitral regurgitant jet size (From Tarnow et al., 2005).  
Data reported as median and 25th-75th percentiles. Results are 





Only a single study has used thromboelastography to assess platelet 
function in CKCS with varying degrees of severity of subclinical CVHD 
(Tarnow et al., 2010); out of 25 dogs, 11 had absent or minimal MVR, and 14 
had severe MVR (regurgitant jet size greater than of equal to 50%). A control 
group of 8 dogs was also included. These authors reported there were no 
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statistically significant differences in thromboelastography variables (R, K, 
MA and α) between the groups, results that did not support global 
hypercoagulability in CKCS with subclinical CVHD (Tarnow et al. 2010b). 
 
1.4.1.4 Platelet activation markers 
 
Platelet surface P-selectin expression  
 
Martini et al. (1996) investigated platelet surface associated P-selectin 
expression in people with varying degrees of severity of MVP. The latter 
study investigated 39 people with absent or mild to moderate MVR, 15 
people with severe MVR and 5 healthy controls and found no difference in P-
selectin expression between groups (Martini et al. 1996). It was not specified 
if the cases were subclinical or clinical and therefore it is unclear whether 
they were congestive heart failure cases or heart disease cases alone. 
 
In contrast, Chung et al. (2007) reported higher P-selectin surface 
expression by flow cytometry, consistent with increased platelet activation, in 
people with acute decompensated congestive heart failure due to impaired 
left ventricular systolic function (22 NYHA class III-IV patients), compared to 
people with stable congestive heart due to impaired left ventricular systolic 
function (53 NYHA class I-II and15 class III-IV patients) and healthy controls 
(n=23). Due to the fact, however, that the number of valvular cases in the 
latter study was not published, an association between decompensated 
valvular disease and increased platelet activation cannot be ascertained. To 
be included in the stable congestive heart failure group there had to be no 
hospital admission for greater than or equal to 3 months. 
 
A single study in dogs has shown no significant difference in platelet surface 
associated P-selectin expression, assessed by flow cytometry, in 31 CKCS 
with either subclinical CVHD or subaortic stenosis compared to control dogs, 
suggesting that platelets do not circulate in a pre-activated form in either 





In people, multiple studies have reported a significant increase in soluble P-
selectin concentration in congestive heart failure compared to controls 
(O’Connor et al. 1999, Gibbs et al. 2001, Yin et al. 2003), including one study 
that included a high proportion (30/74) of valvular heart disease cases (Yin et 
al. 2003). In addition, soluble P-selectin concentrations increased with 
congestive heart failure severity in the latter study. 
 
Soluble P-selectin concentration, as an indicator of platelet activation, has 
not been investigated in dogs with any form of heart disease. 
 
Platelet specific granular proteins i.e. β-thromboglobulin and platelet 
factor 4 
 
The concentrations of platelet specific proteins released from alpha granules, 
in particular BTG and PF4, have been used to assess platelet activation in 
people with MVP and/or MVR with conflicting results. Approximately half of 
all these studies report BTG and/or PF4 concentrations consistent with in 
vivo platelet activation (Cudillo et al. 1983, Fisher et al. 1983, Arocha et al. 
1985, Tse et al. 1997). By contrast, the other half of the literature reports no 
significant difference in BTG or PF4 concentrations between MVP patients 
and controls (Scharf et al. 1982, Lin et al. 1989, Martini et al. 1996).  
 
Commercial antibodies against canine BTG are currently unavailable 











Plasma metabolite thromboxane B2  
 
To the author’s knowledge, no studies have studied thromboxane B2 
concentrations in valvular disease in people. A single study reported no 
significant difference in plasma thromboxane B2 concentration assessed by 
ELISA, in CKCS with varying degrees of severity of subclinical CVHD 
compared to a control population (Tarnow et al. 2005). 
 
Mean platelet component concentration  
 
Chung et al. (2007) reported a decrease in MPC concentration, consistent 
with increased platelet activation, in people with stable congestive heart 
failure due to impaired left ventricular systolic function (53 NYHA class I-II 
and 15 class III-IV patients) compared to healthy controls (n=23) but not in 
acute decompensated congestive heart failure cases (22 NYHA class III-IV 
patients) compared to controls. However, as the number of MVP cases was 
not reported, an association between valvular disease and increased platelet 
activation could not be ascertained.  MPC concentration, as an indicator of 
platelet activation, has not been investigated in dogs with any form of heart 
disease (including valvular disease). 
 
1.4.2 Significance of increased platelet activation/function in 
dogs with chronic valvular heart disease 
 
From the foregoing review, it is apparent that the nature and extent of 
platelet dysfunction associated with valvular disease in dogs is not 
completely clear.  In addition, the consequence(s) of potentially altered 
platelet function in dogs with CVHD is unclear. It is theorised that activated 
platelets may contribute to the development of vascular changes such as 
arteriosclerosis of intra-myocardial coronary arteries and myocardial 
microthrombosis (Patterson et al. 1961, Jönsson 1972, Whitney 1976, 
Tarnow et al. 2005). One study reported that these changes were 
accompanied by focal myocardial necrosis/fibrosis (Patterson et al. 1961). 
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This could result in decreased myocardial oxygenation (and progression of 
heart disease) (Falk and Jönsson 2000). Studies in both dogs and people 
have reported an association between intra-myocardial coronary 
arteriosclerosis and risk of sudden death (Burke and Virmani 1998, Falk and 
Jönsson 2000).  
 
More recently, a study reported that 21 dogs with congestive heart failure 
due to CVHD had significantly advanced intra-myocardial arteriosclerosis 
and myocardial fibrosis compared to 21 age-matched control dogs 
euthanased for reasons not associated with cardiac disease (Falk et al. 
2006). A direct association between the degree of arterial change and clinical 
signs of CHVD has also been demonstrated (Falk et al. 2007). 
 
Arterial pathology is common in the CKCS breed (Buchanan et al. 1997, 
Karlstam et al. 2000). Karlstam et al. (2000) reported pulmonary artery 
lesions (including moderate to severe intimal thickening) associated with 
moderate to severe CVHD in seven consecutive CKCS post mortem 
examinations. Additionally, another CKCS study reported the presence of 
intimal thickening and breaks in the internal elastic lamina of the femoral 
artery with associated thrombosis and vascular occlusion (Buchanan et al. 
1997). 
 
In conclusion, a direct link between arterial pathology and CVHD in dogs has 
not been determined; however, both conditions commonly coexist. It has 
been theorised that activated platelets could contribute to the development of 
vascular changes and myocardial microthrombi and subsequently, heart 
disease progression, and that narrowing of intra-myocardial arteries due to 
coronary arteriosclerosis could produce high shear stresses which in turn 




2 Project Aims and Hypotheses 
 
As noted in the literature review, few studies have assessed platelet 
activation markers in CVHD in dogs. Therefore, the present study sought: 
 
1. To determine the frequency of CVHD in a population of CKCS in Western 
Australia. 
 
2. To characterise and compare platelet indices in the above CKCS 
 To assess automated platelet indices in the CKCS. 
 Due to the inherent variation in platelet number and size in the 
CKCS, the assessment of individual platelet indices in this 
breed is of interest. The exploration of individual platelet 
indices (such as PCT) and the association between platelet 
indices (such as MPV and platelet count) forms the basis for 
the first aim of this present study. 
 To assess the agreement between two platelet counting methods 
(blood smear estimate and optical count) in CKCS with 
macrothrombocytopenia.  
 Despite improved accuracy over impedance counters, the 
Advia 120 may have some difficulty differentiating large 
platelets from erythrocytes at lower counts (Tvedten et al. 
2012). Therefore a further aim was to assess the agreement 
between platelet counting methods (Advia 120 and blood 
smear estimation). We hypothesise that despite improved 
accuracy over impedance counters, the Advia 120 may still 
underestimate platelet counts in cases of macrothrombocytosis 
(Tvedten et al. 2012). 
 To assess the prevalence of macrothrombocytopenia in a population 
of CKCS in Western Australia. 
 The prevalence of macrothrombocytopenia has not previously 
been reported in Western Australia. We hypothesise that 
Western Australian CKCS have a high prevalence of 
59 
 
macrothrombocytopenia as previously reported in another 
Australian state and overseas. 
 To assess the validity of the Advia 120 APCC for the detection of 
platelet clumps in dogs. 
 No previous study has reported on the APCC in clinically well 
dogs. Therefore a minor aim was to assess the validity of the 
Advia 120 APCC for detecting platelet clumps in dogs.  
 
3. To document platelet activation and function and in dogs with subclinical 
CVHD.  
 Significantly longer closure times have been described in CKCS with 
moderate to severe MVR than for those with minimal or mild 
regurgitation or healthy control dogs (Tarnow et al. 2003, Tarnow et 
al. 2004, Tarnow et al. 2005). This finding is due to quantitative and 
qualitative changes in VWF, rather than an alteration of intrinsic 
platelet function. Concurrent alteration of platelet function or platelet 
activation however cannot be excluded. A relatively novel marker of 
platelet activation, MPC concentration, has been reported in dogs 
(Moritz et al. 2003, Moritz et al. 2005, Bauer et al. 2012) but the 
change in MPC concentrations in CVHD is unknown. A 2005 study by 
Moritz et al., suggested that MPC concentration may be more 
sensitive than P-selectin at detecting platelet activation. From MPC 
concentration, the PCDW, an indicator of the variation in platelet 
density is derived. PCDW is high if both non-degranulated and 
degranulated circulating platelets are present. An increased PCDW is 
therefore also a marker of platelet activation (Moritz et al. 2005, 
Boudreaux 2010b).  
 
4. To determine the factors associated with alterations in markers of platelet 
activation and function in dogs with subclinical CVHD.  
 We hypothesise that as heart disease advances, MPC concentration 
will decrease (representing platelet activation), and PCDW will 
increase (representing a variation in platelet density) and that closure 
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time will increase with advancing heart disease severity (representing 
decreased platelet function). Additional confounding factors, such as 








Cavalier King Charles Spaniels  
Client-owned CKCS were prospectively recruited from the Murdoch 
University Veterinary Hospital (MUVH), primary care veterinary practices, 
and CKCS breeders. Recruitment was sought via distribution of recruitment 
flyers to CKCS owners who attended MUVH, posting of a recruitment flyer, in 
the March 2012 edition of the MUVH’s bulletin, posting of a recruitment flyer 
in the April 2012 Western Australian Division of the Australian Veterinary 
Association’s Bulletin, phone contact of CKCS breeders who had previously 
attended MUVH for heart scoring, email contact with referring veterinarians 
and informal word-of-mouth recruitment. 
 
Dogs were recruited from September 2011 through June 2013. Dogs were 
eligible for inclusion if they were greater than or equal to 6 months old and 
apparently healthy (defined as the absence of systemic or organ-related 
disease, other than the presence of a left apical systolic murmur or dental 
disease) as determined by an interview with the owner and results of a 
health questionnaire and physical examination. Dogs that received any drug 
(other than a routine prophylactic antiparasitic drug or vaccination) within 8 
weeks prior to participation were excluded. Age, sex, and body weight of 
each dog were recorded. 
 
Control dogs 
A control group of healthy dogs of breeds other than CKCS was included for 
comparison of platelet indices. Client-owned dogs that were not of CKCS 
breed were retrospectively recruited on the basis of review of the MUVH 
database for the period of November 2011 through May 2013. Dogs were 
included if they were greater than or equal to 6 months old, were apparently 
healthy (defined as the absence of systemic or organ-related disease, other 
than the presence of dental disease, cutaneous masses less than 1 cm 
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diameter that appeared non-painful, or orthopaedic disease), and had 
haematologic analysis performed by use of the Advia 120. Dogs that 
received any drug (other than routine prophylactic antiparasitic drugs or 
vaccinations) within 8 weeks prior to participation or had a heart murmur or 
incomplete medical records were excluded. The reason for admission, 
signalment (age, sex, and breed), body weight, platelet count, MPC 
concentration, PCDW, MPV, PDW, PCT, large platelet index and HCT were 
recorded. 
 
Signed owner consent was obtained for all CKCS participating in the study. 
The study was approved by the Murdoch University Animal Ethics 
Committee (R2443/11). 
 
3.2 Clinical heart evaluation 
 
3.2.1 Murmur intensity/grade 
 
Cardiac auscultation of each CKCS was performed prior to 
echocardiographic assessment by a Diplomate of the European College of 
Veterinary Internal Medicine - Companion Animals (Internal Medicine) or 
Fellow of the Australian and New Zealand College of Veterinary Scientists in 
Small Animal Internal Medicine. The presence or absence, intensity (grades I 
through VI) (Table 3.9), location, and character of each murmur were 
recorded (Tilley et al. 2006).  
 
Murmur grade Murmur intensity 
I Very soft 
II Soft 
III 
Moderate (as loud as the 
heart sounds S1, S2) 
IV Loud 
V Loud with precordial thrill 
VI Very loud 
 





Echocardiography was performed with an ultrasonography system 
(ACUSON SequoiaTM 512, Siemens, San Jose, CA). Each CKCS was 
examined while positioned in right and left lateral recumbency. No chemical 
restraint was used. All examinations were performed by a single investigator, 
an Internal Medicine Resident (Linda Tong), and all recorded images were 
reviewed by a Diplomate of the European College of Veterinary Internal 
Medicine - Companion Animals (Cardiology) (Anne French). Examinations 
were performed both with and without colour flow mapping by use of a 4- to 
10-Hz and 1- to 4-Hz electronic sector transducer, respectively. 
 
3.3.1 Echocardiographic evaluation of left heart remodelling 
 
The LVDD and LVDS were measured by use of M-mode echocardiography 
at the level of the chordae tendinae as guided by a 2-dimensional right 
parasternal short axis view (Thomas et al. 1993). LVDD and LVDS were 
measured when the left ventricle was at its largest and smallest diameter 
respectively. Measurements were made using a leading edge methodology 
(from the anterior-most edge of endocardial lines); to include the proximal but 
not the distal endocardium for each measurement (Sahn et al. 1978). A 
simultaneous ECG was not recorded during echocardiography. The reported 
measurement (in cm) for each dog was the mean of 3 measurements 
normalised on the basis of body weight by use of the following equations 
(Cornell et al. 2004): 
LVDDN = LVDD/(body weight in kg)0.294 
LVDSN = LVDS/(body weight in kg)0.315 
Reference intervals for LVDDN and LVDSN were 1.27 to 1.85 and 0.71 to 
1.26, respectively (Cornell et al. 2004). 
 
Left atrial and aortic root diameters were measured by use of a 2-
dimensional right parasternal short-axis view at the level of the aortic valve 
(Thomas et al. 1993) when the left atrium was subjectively, at its maximal 
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diameter. These diameter measurements were used to calculate LA:Ao. The 
reported LA:Ao was the mean of 3 ratios calculated from 3 paired 
measurements. The criterion for left atrial enlargement was LA:Ao greater 
than 1.5. 
 
Cardiac remodelling was defined as the presence of left atrial enlargement 
(LA:Ao greater than 1.5), left ventricular enlargement (LVDDN or LVDSN 
above reference interval), or both (Hansson et al. 2002, Häggstrӧm et al. 
2008). 
 
3.3.2 Echocardiographic assessment of mitral valve regurgitation 
 
Presence of MVR and estimation of the severity was made with colour flow 
Doppler echocardiography by use of the left apical 4-chamber view with the 
dogs positioned in left lateral recumbency (Thomas et al. 1993). Images 
were analysed frame by frame to estimate the percentage of the left atrium 
occupied by the largest mitral jet (jet size) as previously reported (Tarnow et 
al. 2003). Mitral valve regurgitation was subsequently classified as absent to 
minimal (jet size < 15%), mild (jet size 15% to 50%), or moderate to severe 
(jet size greater than 50%), as reported elsewhere (Tarnow et al. 2003, 
Tarnow et al. 2004). 
 
3.3.3 Canine chronic valvular heart disease score  
 
Based upon clinical and echocardiographic findings, CKCS were grouped 














No identifiable structural disorder of the heart, but high risk for 
developing heart disease (eg. every Cavalier King Charles Spaniel 
without a heart murmur) 
B1 
Asymptomatic patients that have no radiographic or 
echocardiographic evidence of cardiac remodelling 
B2 
Asymptomatic patients that have haemodynamically significant valve 
regurgitation, as evidenced by radiographic or echocardiographic 
findings of left-sided heart enlargement 
C 
Past or current clinical signs of heart failure associated with structural 
heart disease 
D 
End-stage disease with clinical signs of heart failure caused by 
CVHD that are refractory to standard therapy 
 
Table 3.10: The American College of Veterinary Internal Medicine 
canine chronic valvular heart disease scoring system. 
 
3.4 Platelet haematology 
 
3.4.1 Blood collection and handling 
 
A blood sample (10 mL) was collected from each CKCS via jugular 
venipuncture with a 21-gauge needle and 10-mL syringe. Two millilitres of 
blood were transferred into a tube containing K3EDTA (Vacuette, Greiner 
Bio-One GmbH, Kremsmünster, Austria), which was used for automated 
haematologic and blood film assessment. Four millilitres were placed into 
two 2-mL tubes containing 3.8% sodium citrate (Sarstedt, Nϋmbrecht, 
Germany), which were used for closure time assessment. The remaining 4 
mL of blood was stored for use in another study. All tubes were filled to the 
manufacturer’s specified volume. Blood was mixed with the anticoagulant by 
gentle inversion of tubes immediately after sample collection. Blood tubes 
were mechanically rotated with a blood tube rotator (Innovative Medical 
Systems Corp, Ivyland, PA.) until processing. Blood was stored at room 
temperature (approximately 25°C).    
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3.4.2 Assessment of platelet number and function 
 
Blood samples were analysed using the Advia 120 haematology system and 
manufacturer-developed multispecies software (version 3.1.8.0-MS, Siemens 
Healthcare Diagnostics, Tarrytown, NY).  All samples were processed within 
40 minutes after collection. Platelet count, MPC concentration, PCDW, MPV, 
PDW, PCT, MPM, PMDW, large platelet index, APCC and HCT were 
recorded. 
 
Assessment of macrothrombocytosis was also made by dividing the number 
of large platelets (reported as a number x 109/L) by the total Advia 120 
platelet count and multiplying this number by 100. If the result was greater 
than 30%, then the dog was considered to have macrothrombocytosis. 
 
Closure time was determined by use of the PFA-100 analyser and collagen-
ADP cartridges in accordance with the manufacturer’s instructions. All 
samples were processed within 60 minutes after collection. Each sample 
was assayed in duplicate. When the coefficient of variation was greater than 
15%, the results were rejected, and a duplicate assay was repeated. Results 
for dogs with a HCT < 0.35L/L were excluded (Clancey et al. 2009b).  
 
3.4.3 Assessment of blood smears 
 
Blood films were prepared from each CKCS sample within 60 minutes of 
sample collection and stained with modified Wright stain (Hematek Stain 
Pak, Siemens, Healthcare Diagnostics Inc., Tarrytown, NY, USA) by use of 
an automated staining instrument (Hematek 1000, Siemens Healthcare 
Diagnostics).  
 
All microscopic examinations were performed under 100-1000X 
magnification, as detailed below. A 10X ocular lens was used in all 
examinations. One investigator (Linda Tong), who was not aware of the 
platelet count, examined each blood film. Blood smear platelet estimates 
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were determined by counting the number of platelets in 10 consecutive oil 
immersion (100X) objective fields in the monolayer area of each blood 
smear. The average number of platelets per field was multiplied by 15 x 
109/L to obtain the platelet estimate as previously described (Tvedten et al. 
2008). 
 
The percentage of macrothrombocytes was determined by counting the 
number of platelets that were subjectively as large as or larger than a red 
blood cell, in the same 10 consecutive oil immersion (100X) objective fields 
used for blood smear estimation (Figure 3.7). The number of 
macrothrombocytes counted was divided by the total number of platelets in 
those fields to provide a macrothrombocyte percentage. If more than 30% of 
the platelets were macrothrombocytes, a diagnosis of macrothrombocytosis 

















Figure 3.7: Blood smear from a 3-year-old CKCS demonstrating 
macrothrombocytes 
(platelets subjectively assessed to be as large as or larger than a 
















Figure 3.8: Blood smear from a 3-year-old CKCS demonstrating 
platelet size variation. 
Normal sized platelet (arrow head) and macrothrombocyte 
(arrow). 
 
The number and size of platelet aggregates were estimated in 5 consecutive 
high-power fields (hpf) (400X magnification) at the feathered edge of each 
blood film. This protocol was a modification of that described in a study 
(Bertazzolo et al. 2007) in which the number and size of platelet aggregates 
were estimated in fields by use of oil immersion (1000X magnification). The 
number of platelet aggregates was judged on a scale of 0 to 3 as follows: 0 = 
absent, 1 = sparse with 1 or 2 aggregates/5 hpfs, 2 = moderately frequent 
with 3 to 5 aggregates/5 hpfs, and 3 = numerous with greater than 5 ag-
gregates/5 hpfs. The size of aggregates was assessed on a scale of 1 to 3 
as follows: 1 = small (3 to 8 platelets), 2 = medium (9 to 20 platelets), and 3 = 








3.5 Statistical analysis 
 
Descriptive variables with continuous data (age, body weight, platelet count, 
MPC concentration, PCDW, and HCT) were tested for normality by use of 
the Shapiro-Wilk test. A normal distribution was determined when there was 
failure to reject the null hypothesis of normality at P < 0.05. Normally dis-
tributed data were summarised as mean and 95% CI. Non-parametric data 
were summarised as median and IQR. Comparisons were made between 
groups by use of Student t tests for parametric variables and the Mann-
Whitney U test for nonparametric variables. Estimated frequencies of select 
variables were summarised as proportion and 95% CI. The distribution of sex 
for each group was compared by use of a Fisher exact test. Comparisons 
among 3 or more categories within CKCS cohorts were performed by use of 
an analysis of variance (ANOVA) for parametric responses or a Kruskall-
Wallis test for nonparametric responses. Pairwise post hoc comparisons 
were performed by use of the least squares mean or the Mann-Whitney U 
test, respectively, with a Bonferonni correction for overall type I error. 
Significance was set at P < 0.05 for all comparisons. 
 
Measured variables for the CKCS group were summarised as described 
previously. Associations between possible explanatory variables (sex, age, 
murmur, jet size, LA:Ao, LVDDN, LVDSN, platelet count, and HCT) and 
outcomes (closure time, MPC concentration, and PCDW) were assessed 
with multivariate regression models using SAS version 9.4 (SAS Institute, 
NC, USA).  The model of best fit was selected on the basis of the Cp statistic 
and consideration of the R2. All possible subsets were evaluated. The best 
models for subsets were selected on the basis of the smallest Cp statistic 
with the least bias (i.e., the Cp statistic closest to p, where p is the number of 
variables in the model). The simplest subsets that explained the outcome 
were chosen with the selected Cp statistic and R2. The proportion of variance 
explained by the explanatory variable or variables, partial R2, and cor-




The level of agreement between platelet-counting methods (blood smear 
estimation and the Advia 120) was assessed using Bland-Altman analysis. 
 
A comparison between automated platelet clump flag and visual detection of 
platelet clumping was calculated using Kappa statistics, with GraphPad® 
software on-line calculator (http://graphpad.com/quickcalcs/kappa1.cfm). 
 









A total of 89 CKCS fulfilled the inclusion criteria; 47 were female (34 spayed 
and 13 entire) and 42 male (38 castrated and 4 entire).  In the control group, 
39 dogs fulfilled the inclusion criteria; 20 were female (17 spayed and 3 
entire) and 19 male (16 castrated and 3 entire). The breeds in the control 
group are detailed in Table 4.11.  
 
Breeds Number of dogs 
Cross breed 15 
Greyhound 4 
Poodle 3 
Labrador retriever 2 
Maltese 2 
Jack Russell terrier 2 
Staffordshire bull terrier 2 
Pekingese 1 
Dachshund 1 
Blue heeler 1 
Cocker spaniel 1 
Schnauzer 1 
Australian cattle dog 1 
German shorthaired pointer 1 
German shepherd dog 1 
Shih Tzu 1 
 
Table 4.11: Dog breeds of the control group (n=39). 
 
There was no significant difference in the frequency of sex between groups 
(P = 0.150; Fisher exact test). 
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Ages and bodyweights of the CKCS and control dogs are summarised in 
Tables 4.12 and 4.13 respectively.  There were significant differences 
between both age and bodyweight of CKCS and control dogs (P < 0.001 and 
P = 0.01, respectively; Mann Whitney). 
 
Age (years) CKCS Control dogs 
Range  0.6-15 0.8-15 
Median  4 9.8 
Interquartile range (IQR) 2-6 5.5-12.3 
 









Table 4.13: Bodyweight of the CKCS (n=89) and control dogs 
(n=39). 
 
4.2 Heart disease 
 
4.2.1 Murmur grade  
 
A left apical systolic murmur was detected in 51 of 89 CKCS (57%; 95% CI, 
46% to 66%).  Of the 51 CKCS with a murmur, 24 (47%) were aged 6 years 
or less. The frequencies of the murmur grades are listed in Table 4.14 and 
the relationship between age and murmur grade is displayed in Figure 4.9. 
There was a positive relationship between murmur grade and age. 
 
 
Bodyweight (kg) CKCS Control dogs 
Range  5-18 3-35 
Median  10.1 20.5 
IQR  8.2-11.6 6.4-29 
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4.2.2 Regurgitant jet size 
 
Mitral valve regurgitation was detected by use of colour-flow Doppler 
echocardiography in 86 of 89 (97%; 95% CI, 90% to 99%) CKCS. The 3 
dogs that had no evidence of MVR were 8 months old, 3 years old, and 4 
years old).  
 
The number of dogs within each regurgitant jet size group is detailed in Table 
4.15. 
 
Severity group Regurgitant jet size (%) n 
Absent-minimal < 15 52 
Mild 15 to 50 14 
Moderate-severe > 50 23 
 
Table 4.15: Regurgitant jet size severity group for 89 CKCS with 
subclinical CVHD.  
 
4.2.3 Echocardiographic indices of left heart remodelling  
 
The results of echocardiographic indices of cardiac remodelling (LA:Ao, 
LVDDN and LVDSN) are shown in Table 4.16 and Figure 4.10. 
 
Left atrial enlargement was evident in 22 of 89 CKCS. Four of 89 CKCS had 
left ventricular enlargement during diastole. Left ventricular enlargement 
during systole was not detected in any CKCS. 
 
 LA:Ao  LVDDN  LVDSN 
Range  1-2.08 0.95-2.06 0.51-1.26 
Mean  1.40 1.40 0.86 
95% CI (mean)  1.35-1.45 1.35-1.44 0.83-0.89 
 






Figure 4.10: LA:Ao, LVDDN and LVDSN values for each CKCS 
(n=89).  
In each graph, the dotted line indicates the upper limit of the 
reference interval.   
 
4.2.4 Canine chronic valvular heart score  
 
The ACVIM canine CVHD scores are summarised below (Table 4.17). As 
only subclinical cases were included in the present study, no dogs were 
classified in Stage C or D 
 















4.3 Platelet enumeration 
 
Cavalier King Charles spaniel Advia 120 and blood smear derived platelet 
counts and control dog Advia 120-derived platelet counts are summarised in 
Table 4.18 and displayed in Figure 4.11. There was a significant difference 
between the Advia 120-derived platelet counts in the CKCS and control dogs 
(P < 0.001; Mann Whitney).  Thrombocytopenia, defined as an Advia 120-
derived platelet count less than 100 x 109/L, was identified in 18 of the 89 
(20%; 95% CI, 13% to 30%) CKCS but was not identified in any of the 
control dogs.  
 




Advia 120 Blood 
smear 
estimate   
Advia 120 
Range 27-565 33-642 123-699 
Median 213 220.5 315 
IQR 143-306 132-296 171-402 
 
Table 4.18: Platelet counts (obtained by the Advia 120 and blood 
smear estimation) in the CKCS (n=89) and (by the Advia 120) in 














Figure 4.11: Platelet counts of the CKCS (obtained by blood 
smear estimation and the Advia 120; n= 89) and control dogs 
(obtained by the Advia 120; n=39). 
Both control dogs with a platelet count of < 200 x 109/L were 
Greyhounds. The dotted line indicates a platelet count of 100 x 
109/L.   
 
Analysis of the agreement between platelet counting obtained by smear 
estimation and the Advia 120 was made using Bland–Altman agreement 
analysis (Figure 4.12). 
  
The plot of the difference between smear estimation and Advia 120 values 
against their means according to the Bland and Altman design, showed a 
bias of -1.82 x 109/L, with a SD of 38.58, and with 92.1% of differences within 
the agreement limits (mean ± 2SD). This confirmed good agreement 






Figure 4.12: Bland Altman plot of two counting methods (blood 
smear estimation and Advia 120) in the CKCS (n=89). 
The difference of platelet values (blood smear-Advia 120) (y-axis) 
is plotted against the mean value (x-axis). The middle solid line is 
the mean of the difference. The dotted lines represent the 95% 
limits of agreement (-77.43 to 73.81). The bias (SD) was -1.82 
(38.58). 
 
The correlation between platelet counts obtained by blood smear estimation 
and Advia 120 was analysed using Spearman’s rank correlation (Figure 






Figure 4.13: Correlation between blood smear estimate and Advia 
120 platelet counts 
 
4.4 Selected haematological and platelet function indices 
 
4.4.1 Plateletcrit  
 
Plateletcrit data for the CKCS and control dogs are summarised in Table 
4.19 and Figure 4.14. The PCT was significantly lower in the CKCS 
compared to control dogs (CKCS: median 0.24%, IQR 0.19-0.29%; control 
dogs: median 0.27%, IQR 0.23-0.36%; P < 0.011; Mann Whitney), but a 
large amount of overlap between the CKCS and control dog results. Despite 
a large number of CKCS with thrombocytopenia, the majority of CKCS had 






Plateletcrit (%) CKCS Control dogs 
Median  0.24 0.27 
Range  0.7-0.48 0.11-0.61 
IQR 0.19-0.29 0.23-0.36 
 





Figure 4.14: Plateletcrit result of each CKCS (n=89) and control 
dog (n=39).  
The dotted lines represent a reference interval of 0.13-0.4% 
(Kelley et al. 2014). 
 
4.4.2 Mean platelet volume  
 
The MPV data for the CKCS and control dogs are summarised in Table 4.20 
and Figure 4.15. The MPV was significantly higher in the CKCS compared to 
control dogs (CKCS: median 11.2 fL, IQR 8.8-16.1 fL; control dogs: median 
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8.6 fL, IQR 8.0-9.1 fL; P < 0.001; Mann Whitney). The reported MPV 
reference interval is 8.56-14.41 fL (Moritz et al. 2004). 
 
MPV (fL) CKCS Control dogs 
Median  11.2 8.6 
Range  7.1-29.4 6.8-11.7 
IQR  8.8-16.1 8.0-9.1 
 
Table 4.20: Mean platelet volume results of the CKCS (n=89) and 




Figure 4.15: Mean platelet volume result of each CKCS (n=89) 
and control dog (n=39). 
The dotted lines represent a reference interval of 8.56-14.41 fL (Moritz 
et al. 2004). 
 
The percentage of large platelets in both CKCS and control dogs, as 
determined by MPV, is displayed in Figure 4.16. Based upon a definition of 
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greater than 30% circulating large platelets, 19 of the 89 CKCS were 
classified as having macrothrombocytosis when assessed by the Advia 120 
(Figure 4.16).  Four of these 19 dogs had greater than or equal to 70% 
circulating large platelets. When macrothrombocytosis was assessed by a 
different methodology, blood smear assessment, five of 89 CKCS were 
classified as having macrothrombocytosis. Two of these 5 dogs were 
classified as having 70% or more macrothrombocytes by the Advia 120. 
 
 
Figure 4.16: Percentage of large platelets (as assessed by the 
Advia 120) for each of the CKCS (n=89) and control dogs (n=39).  
Each data point above the dotted line represents a CKCS with 
greater than 30% circulating large platelets (n = 19).  
 
The MPV was inversely related to platelet count in the CKCS (Figure 4.17) 
but not in the control dogs; the latter group had similar MPV across platelet 




Figure 4.17: Graph displaying the relationship between MPV and 
platelet count for 89 CKCS. 










Figure 4.18: Graph displaying the relationship between MPV and 
platelet count for 39 control dogs. 
The dotted line indicates a platelet count of 100 X 109/L. 
 
Two control dogs had a platelet count less than 200 x 109/L (123 x 109/L and 
143 x 109/L) but MPV within reference interval (8.56 and 14.4 fL 
respectively). Both dogs were Greyhounds, a breed also recognised for 
inherited thrombocytopenia, but not macrothrombocytosis.  
 
4.4.3 Platelet volume distribution width  
 
The PDW data for the CKCS and control dogs are summarised in Table 4.21 
and Figure 4.19. The PDW was significantly higher in the CKCS compared to 
control dogs (CKCS: median 59.7%, IQR 52.4-68.5%; control dogs: median 
57.4%, IQR 53.2-59.3%; P = 0.044; Mann Whitney), with a large amount of 
overlap between groups. The reported PDW reference interval is 55.71-





Platelet volume distribution width (%) CKCS Control dogs 
Median  59.7 57.4 
Range  44.3-78.2 44-67.2 
IQR  52.4-68.5 53.2-59.3 
 
Table 4.21: Platelet volume distribution width results of the CKCS 




Figure 4.19: Platelet volume distribution width of each CKCS 
(n=89) and control dog (n=39).  
The dotted lines represent a reference interval of 55.71-66.9% (Moritz 
et al. 2004).  
 
 
4.4.4 Advia 120 large platelet count 
 
The Advia 120 large platelet data for the CKCS and control dogs are 
summarised in Table 4.22. 
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The large platelet count was significantly higher in the CKCS compared to 
control dogs (CKCS: median 20 x 109/L, IQR 9-30 x 109/L; control dogs: 
median 8 x 109/L, IQR 4.5-13 x 109/L; P < 0.001; Mann Whitney). 
 
Advia 120 large platelet count (x 109/L) CKCS Control dogs 
Median  20 8 
Range  2-47 2-40 
IQR  9-30 4.5-13 
Advia 120 large platelet percent (%) CKCS Control dogs 
Median 9.78 2.55 
Range 0.48-72.41 0.71-12.7 
IQR 2.6-24.1 1.53-3.87 
 
Table 4.22: Advia 120 large platelet results of the CKCS (n=89) 
and control dogs (n=39). 
 
4.4.5 Assessment of platelet clumping – Cavalier King Charles 
spaniel 
 
Platelet aggregates were visually identified in 44 of 89 samples. Number of 
platelet aggregates was judged as sparse, moderately frequent, and 
numerous in 26, 9, and 9 blood films, respectively. Aggregate size was 
classified as small, medium, or large in 14, 16, and 14 samples, respectively. 
In the 18 CKCS with thrombocytopenia, sparse, moderately frequent, and 
numerous numbers of aggregates were identified in 3, 3, and 5 samples, 
respectively. Small, medium, and large aggregates were identified in 7, 2, 
and 2 samples, respectively. No platelet aggregates were identified in the 
remaining 7 CKCS. There was no significant difference in closure time, MPC 
concentration, or PCDW between CKCS with and without platelet aggregates 
(P = 0.095; Student t test) or between categories for number of aggregates 
(P = 0.134; ANOVA) or size of platelet aggregates (P = 0.06; ANOVA). 
 
Platelet clumping results in the CKCS using two methods (visual clump 













Advia 120 clump  
flag +ve (APCC > 
300) 
(number of dogs) 
Advia 120 clump 
flag –ve (APCC ≤ 
300) 
(number of dogs) 
3 3+ 4 2 2 
3 2+ 3 1 2 
3 1+ 7 3 4 
2 3+ 1 1 0 
2 2+ 4 2 2 
2 1+ 11 6 5 
1 3+ 4 4 0 
1 2+ 2 2 0 
1 1+ 8 5 3 
N/A 0 45 26 19 
Total  89 52 37 
 
Table 4.23: Platelet clumping results in the CKCS using visual 
clump assessment and the Advia 120 clump flag (n=89). 
 
To determine how the automated platelet clump flag compared with visual 
detection of platelet clumping, the number of samples with APCC less than 
or equal to 300 (Advia 120 clump flag –ve) or greater than 300 (Advia120 
clump flag +ve) and those with or without visual detection of platelet clumps 
were compared using Kappa statistics. For this comparison visual platelet 
scores were dichotomised into “visual clumping” (size and number 1 through 












 Advia 120 clump  
flag +ve 
Advia 120 clump  
flag -ve 
Total 
Visual clumping 26 18 44 
No visual clumping 26 19 45 
Total 52 37 89 
 
Table 4.24: Visual platelet scores (clumping/no clumping) against 
the Advia 120 platelet clump flag in the CKCS (n=89). 
 
There were 45/89 observed agreements. The Kappa statistic (95% 
confidence interval) was 0.013 (-0.191 to 0.217), consistent with a poor 
strength of agreement. The standard error of Kappa was 0.104. The Advia 
120 flagged clumps in 26 of 45 samples without visually detected clumps 
(specificity of 42%) and failed to flag clumps in 18 of 44 samples in which 
platelet clumps were detected visually (sensitivity of 59%). 
 
Subsequently, clump size and clump number (Table 4.25 and 4.26 
respectively) were individually compared with the results of the Advia 120 
clump flag. The results demonstrate that an increase in clump size does not 
result in an improved ability of the APCC to detect clumps.  
 
Clump size Advia 120 clump flag +ve Advia 120 clump flag -ve 
1 11 3 
2 9 7 
3 6 8 
 
Table 4.25: Clump size (based on visual assessment) compared 









Clump number Advia 120 clump flag +ve Advia 120 clump flag -ve 
1+ 14 12 
2+ 5 4 
3+ 7 2 
 
Table 4.26: Clump number (based on visual assessment) 
compared with the Advia 120 platelet clump flag status in the 
CKCS. 
 
4.4.6 Closure time – Cavalier King Charles spaniel 
 
Closure time was recorded for 76 of 89 CKCS. Closure time was unavailable 
for 12 CKCS because of failure to perform duplicate assays with the PFA-
100 and for 1 CKCS because it had an HCT less than 0.35 L/L. The median 
closure time was 73 seconds (IQR, 62 to 102 seconds; Table 4.27). The 
reported reference interval for CT is 52-86 seconds (Callan and Giger 2001). 
Closure time was greater than the upper limit of the reference interval for 27 
CKCS. 
 
The closure time data for the CKCS is summarised in Table 4.27 and Figure 
4.20. 
 
Closure time (seconds) CKCS 
Median  73 
Range  52-210.5 
IQR  62-102 
 





Figure 4.20: Closure time result in the CKCS (n=76).  
The dotted line represents a previously reported upper end of the 
reference interval limit of 86 seconds (Callan et al. 2001).  Twenty 
seven (35.5%) closure time results were above the reference 
interval. 
 
4.4.7 Mean platelet component concentration 
 
The MPC concentration data for CKCS and control dogs are summarised in 
Table 4.28 and Figure 4.21. The MPC concentrations were significantly 
higher in the CKCS compared to control dogs (CKCS: mean 209 g/L, 95% CI 
of the mean 207-211 g/L; control dogs: mean 204 g/L, 95% CI of the mean 
199-208 g/L; P = 0.017; Student t test). There was a large amount of overlap 
between groups.  
The reported MPC concentration reference interval is 140-186.3 g/L (Moritz 






MPC (g/L) CKCS Control dogs 
Mean  209 204 
Range  184-241 168-233 
95% CI of the mean 207-211 199-208 
 
Table 4.28: Mean platelet component concentration results of the 




Figure 4.21: Mean platelet component concentration of each 
CKCS (n=89) and control dog (n=39). 
The dotted lines represent a reference interval of 140-186.3 g/L 
(Moritz et al. 2004).  
 
4.4.8 Platelet component distribution width   
 
The PCDW data for the CKCS and control dogs are summarised in Table 
4.29 and Figure 4.22. The PCDW was significantly lower in the CKCS 
compared to control dogs (CKCS: mean 41 g/L, 95% CI of the mean 39-43 
g/L; control dogs: mean 54 g/L, 95% CI of the mean 50-57 g/L; P < 0.001; 
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Student t test), with a large amount of overlap between groups. The reported 
PCDW reference interval is 45.8-70.5 g/L (Moritz et al. 2004). 
PCDW (g/L) CKCS Control dogs 
Mean  41 54 
Range  27.4-68.8 35.2-75.7 
95% CI of the mean 39-43 50-57 
 
Table 4.29: Platelet component distribution width results of the 
CKCS (n=89) and control dogs (n=39). 
 
 
Figure 4.22: Platelet component distribution width of each CKCS 
(n=89) and control dog (n=39). 
The dotted lines represent a reference interval of 45.8-70.5 g/L (Moritz 
et al. 2004).  
 
4.4.9 Haematocrit  
 
The HCT data for the CKCS and control dogs are summarised in Table 4.30 
and Figure 4.23. The HCT values were significantly lower in the CKCS 
compared to control dogs (CKCS: mean 0.41 L/L, 95% CI of the mean 0.4-
0.42 L/L; control dogs: mean 0.5 L/L, 95% CI of the mean 0.48-0.52 L/L; P < 
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0.001; Student t test). The HCT reference interval is 0.42-0.62 L/L (Moritz et 
al., 2004). 
 
Haematocrit (L/L) CKCS Control dogs 
Mean  0.41 0.5 
Range  0.34-0.47 0.37-0.6 
95% CI of the mean  0.40-0.42 0.48-0.52 
 






Figure 4.23: Haematocrit of each CKCS (n=89) and control dog 
(n=39). 
The dotted lines represent a reference interval of 0.42-0.62 L/L 
(Moritz et al. 2004). The majority of the CKCS and control dogs 






4.4.10 Mean platelet mass  
 
The MPM data for the CKCS and control dogs are summarised in Table 4.31 
and Figure 4.24. The MPM was significantly higher in the CKCS compared to 
control dogs (CKCS: median 2.10 pg, IQR 1.66-2.62 pg; control dogs: 
median 1.59 pg, IQR 1.51-1.67 pg; P < 0.001; Mann Whitney), with a large 
amount of overlap between groups. The reported MPM reference interval is 
1.32-1.92 pg (Moritz et al. 2004).  
 
Mean platelet mass (pg) CKCS Control dogs 
Median  2.10 1.59 
Range  1.36-3.59 1.32-2.23 
IQR  1.66-2.62 1.51-1.67 
 
Table 4.31: Mean platelet mass results of the CKCS (n=89) and 
control dogs (n=39). 
 
 
Figure 4.24: Mean platelet mass of each CKCS (n=89) and 
control dog (n=39). 
The dotted lines represent a reference interval of 1.32-1.92 pg (Moritz 
et al. 2004).  
95 
 
4.4.11 Platelet mass distribution width  
 
The PMDW data for the CKCS and control dogs are summarised in Table 
4.32 and Figure 4.25. The PMDW was significantly higher in the CKCS 
compared to control dogs (CKCS: median 0.87 pg, IQR 0.67-1.0 pg; control 
dogs: median 0.61 pg, IQR 0.56-0.65 pg; P < 0.001; Mann Whitney), with a 
large amount of overlap between groups. The reported PMDW reference 
interval is 0.51-0.84 pg (Moritz et al. 2004). 
 
Platelet mass distribution width (pg) CKCS Control dogs 
Median  0.87 0.61 
Range  0.49-1.31 0.46-0.86 
IQR  0.67-1.00 0.56-0.65 
 
Table 4.32: Platelet mass distribution width results of the CKCS 













Figure 4.25: Platelet mass distribution width of each CKCS (n=89) 
and control dog (n=39). 
The dotted lines represent a reference interval of 0.51-0.84 pg (Moritz 
et al. 2004).  
 
4.5 Association analysis 
 
Platelet activation and function has the potential to be affected by turbulent 
high-velocity blood flow and fluid shear stress associated with valvular heart 
disease. Association analysis was performed to investigate platelet activation 
and function in dogs with varying severity of subclinical mitral regurgitation. 
 
4.5.1 The association of closure time with heart disease and 
selected haematological indices 
 
The association of closure time with measures of CVHD severity, platelet 
count (Advia 120), HCT, age, sex and bodyweight was explored using 




Complete data were available for 76 CKCS (Table 4.33). A model with 5 
variables best explained the variation in closure time, with regurgitant jet size 
exerting the largest effect. The LA:Ao, age, sex, body weight, and HCT had 
no significant effect on closure time in the multiple linear regression 
analyses. Closure times differed significantly (P < 0.001; ANOVA) among 
regurgitant jet sizes; CKCS with a jet size greater than 50% had a 
significantly (P < 0.001; least squares mean) longer closure time than did 
CKCS with a jet size less than 15% or CKCS with a jet size of 15% to 50% 
(Table 4.34; Figure 4.26). 
 
 




















                    
Regurgitant jet size 0.61 0.61 35.2 < 0.001 
LVDDN 0.06 0.67 23.2 0.001 
Murmur grade 0.03 0.70 16.7 0.009 
Platelet count 0.02 0.72 13.0 0.026 
LVDSN 0.02 0.74 8.6 0.015 
Model                      n/a 0.74 8.6 0.015 
MPC 
concentration 
(n=89)               
Platelet count 0.24 0.24 -1.8 < 0.001 
Model    n/a 0.24 -1.8 < 0.001 
PCDW  
(n=89) 
                          
Platelet count 0.21 0.21 1.25 < 0.001 
Sex 0.04 0.25 4.86 0.030 
Model n/a 0.25 4.86 0.030 
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Severity group Regurgitant jet size (%)* n Closure time (s) 
Absent-minimal < 15 43 67 (64-70) 
Mild 15 to 50 12 78 (65-92) 
Moderate-severe > 50 21 138 (122-155)† 
 
Table 4.34: Regurgitant jet size and corresponding closure time 
values (mean [95% CI]) for 76 CKCS. 
*Regurgitant jet size was < 15%, 15% to 50% and > 50% for 52, 
14, and 23 CKCS respectively; in the 89 CKCS, however, CT was 
not determined in 13 dogs, hence the results for 76 CKCS in this 
table. † Value differs significantly (P < 0.001) from the value for 










Figure 4.26: Graph displaying closure time for 76 CKCS that had 
regurgitant jet size < 15% (n = 43), 15% to 50% (n = 12), and > 
50% (n = 21). 
The closure time was significantly (P < 0.001; least squares mean) 
longer for CKCS with regurgitant jet size > 50%, compared with 
closure time for dogs with regurgitant jet size < 15% or 15% to 
50%. 
  
4.5.2 The association of mean platelet component concentration 
and platelet component distribution width with heart 
disease and selected haematological indices 
 
The association of MPC concentration and PCDW with measures of CVHD 
severity, platelet count (Advia 120), HCT, age, sex and bodyweight was 




Complete data were available for 89 CKCS. The model that best explained 
the variation in MPC concentration included only platelet count (Table 4.33). 
The model that best explained the variation in PCDW included platelet count 
and sex. The relationship between MPC concentration and platelet count 
(Figure 4.27) and between PCDW and platelet count (Figure 4.28) are 
graphed. 
 
Five of the 7 data points with the highest platelet counts and lowest MPC 
concentrations represented samples without platelet clumping (Figure 4.27). 
 
There was a significant negative association of MPC concentration with 
platelet count (R2 = 0.24, P <0.001) (Table 4.33).  
 
There was a significant positive association of PCDW with the platelet count 
(R2 = 0.21, P < 0.001). In addition, sex was found to be a weak component of 









Figure 4.27: Graph displaying the relationship between MPC 
concentration and platelet count for 89 CKCS. 
The red data points represent dogs with a MPV of > 20 fL i.e. the 
dogs with larger platelets. Multiple regression analysis revealed 
that a model containing only 1 variable (platelet count) best 






Figure 4.28: Graph displaying the relationship between PCDW 
and platelet count for 89 CKCS (42 males [white squares] and 47 
females [black circles]). 
The PCDW increases with increasing platelet count (consistent 
with increased variation in platelet density with increasing platelet 
count). The red data points represent dogs with a MPV of > 20 fL 
i.e. the dogs with larger platelets. Multiple regression analysis 
revealed that a model containing 2 variables (platelet count and 
sex) best explained the variation in PCDW (platelet count partial 
R2, 0.21; model R2, 0.25 [P = 0.03]). 
 
4.5.3 The association of mean platelet volume with heart disease 
and selected haematological indices 
 
The association of MPV with measures of CVHD severity, platelet count 





There was a significant negative association of MPV with the platelet count 
(R2 = 0.61, P < 0.001) (Figure 4.17 and Table 4.35). 
 
Age, sex, body weight, HCT and heart disease indices had no significant 




         Table 4.35: Results of MPV multiple regression analysis. 
 
4.5.4 The association of platelet volume distribution width with 
heart disease and selected haematological indices 
 
The association of PDW with measures of CVHD severity, platelet count 
(Advia 120), HCT, age, sex and bodyweight was explored using multiple 
regression analysis. 
 
There was a significant, complex association of PDW with the platelet count 
(R2 = 0.05, P = 0.044) (Table 4.36). Figure 4.29 displays the PDW of each 
dog against platelet count. 
 
Age, sex, body weight, HCT and heart disease indices had no significant 




Table 4.36: Results of PDW multiple regression analysis. 
 
 
 Partial R-square Model R-square P value 
Platelet count 0.61 0.61 < 0.001 
 Partial R-square Model R-square P value 




Figure 4.29: Graph displaying the relationship between PDW and 
platelet count for 89 CKCS.  
The red data points represent dogs with a MPV of > 20 fL i.e. the 
dogs with larger platelets. 
 
4.5.5 The association of mean platelet mass with heart disease 
and selected haematological indices 
 
The association of MPM with measures of CVHD severity, platelet count 
(Advia 120), HCT, age, sex and bodyweight was explored using multiple 
regression analysis. 
 
There was a negative association of MPM with the platelet count (R2 = 0.80, 
P < 0.001). In addition jet size was found to be a weak component of the 
model (R2 =0.01, P = 0.02) (Table 4.37). Figure 4.30 displays the MPM of 
each dog against platelet count. 
Age, sex, body weight, HCT and heart disease indices (excluding jet size) 








Table 4.37: Results of MPM multiple regression analysis. 
 
 
Figure 4.30: Graph displaying the relationship between MPM and 
platelet count for 89 CKCS. 
MPM is higher at lower platelet counts, and that MPM decreases 
as platelet count increases. The red data points represent dogs 
with a MPV of > 20 fL i.e. the dogs with larger platelets. 
 
To test the hypothesis that larger platelets have more granules than 
smaller platelets (since lower platelet counts are associated with larger 
platelet size), MPM was subsequently plotted against MPV (Figure 4.31).  
 
 Partial R-square Model R-square P value 
Platelet count 0.80 0.80 < 0.001 




Figure 4.31: Graph displaying the relationship between MPM and 
MPV for 89 CKCS. 
Visual inspection of the graph revealed a positive relationship 
between MPM and MPV.  
 
4.5.6 The association of platelet mass distribution width with 
heart disease and selected haematological indices 
 
The association of PMDW with measures of CVHD severity, platelet count 
(Advia 120), HCT, age, sex and bodyweight was explored using multiple 
regression analysis. 
 
There was a significant complex association of PMDW with the platelet count 
(R2 = 0.53, P < 0.001). In addition murmur grade was found to be a weak 
component of the model (R2 = 0.03, P = 0.013) (Table 4.38). Figure 4.32 
displays the PMDW of each dog against platelet count. 
Age, sex, body weight, HCT and heart disease indices (excluding murmur 













Figure 4.32: Graph displaying the relationship between PMDW 
and platelet count for 89 CKCS. 
The red data points represent dogs with a MPV of > 20 fL i.e. the 
dogs with larger platelets. 
  
 Partial R-square Model R-square P value 
Platelet count 0.53 0.53 < 0.001 





The primary objective of this present study was to investigate associations 
between markers of heart disease severity and platelet function or activation. 
Although 5 variables significantly affected closure time, the regurgitant jet 
size exerted by far the largest effect, as previously described (Tarnow et al. 
2003). This may have reflected quantitative and qualitative changes in VWF 
rather than an alteration of intrinsic platelet function (Tarnow et al. 2004). 
 
Comparison across jet size categories showed that the closure time of CKCS 
with jet size greater than 50% was significantly higher than that of CKCS with 
jet size less than 15% and 15-50% (P < 0.0001). These results are similar to 
a previous study (Tarnow et al. 2003), however in the latter study the closure 
time of CKCS with jet size greater than 50% was significantly higher than 
that of CKCS with jet size less than 15% but not dogs with jet size 15-50%. 
In addition, in the aforementioned study the closure time of CKCS with jet 
size 15-50% was different to CKCS with closure time less than 15%. 
 
There was no association between closure time and age, sex, body weight, 
LA:Ao and HCT. The lack of an association between closure time and age, 
sex, body weight and LA:Ao is in line with the results of a previous study 
(Tarnow et al. 2003). The lack of an association between closure time and 
HCT, however, contradicts the results of Tarnow et al. (2003) and is difficult 
to explain. This result is not likely due to exclusion of dogs with HCT less 
than 0.35L/L in this present study because only one dog was excluded for 
this reason. 
 
By contrast, none of the indicators of heart disease severity significantly 
affected MPC concentration or PCDW. This suggested that platelet activation 
was not a feature of valvular heart disease in CKCS, which supports results 
of thromboelastography and evaluation of P-selectin expression and 
thromboxane concentrations (Tarnow et al. 2005). In humans with cardiac 
disease, valvular changes or associated alterations in blood flow are 
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believed to initiate platelet adherence and aggregation, which potentially 
leads to thromboembolic complications (Barnett et al. 1976, Kostuk et al. 
1977). Significantly increased platelet aggregation responses and plasma 
concentrations of PF4 and BTG have been described for humans with 
combined MVP and MVR, compared with results for healthy control subjects 
(Walsh et al. 1981, Tse et al. 1997). Similarly, an increase in MPV, which is 
suggestive of platelet activation, has been observed in a variety of human 
cardiac diseases, including MVP (Varol et al. 2009, Icli et al. 2013). Reasons 
for the apparent differences in platelet activation between heart disease in 
dogs and humans remain unclear. Presumably, platelet reactivities or 
pathogenic mechanisms that incite activation differ between the species. 
Mean platelet component concentration was the platelet activation marker of 
choice in the present study because it was theorised that decreased platelet 
density (i.e decreased MPC concentration) may be detectable after the loss 
of cell-surface P-selectin (Macey et al. 1999) and the results of a previous 
study (Moritz et al. 2005) suggested that MPC concentration may be a more 
sensitive indicator of platelet activation than P-selectin. Furthermore it was 
expected that MPC concentration, being a measure of platelet density would 
be less affected by the CKCS inherent variation in platelet size, unlike other 
proposed platelet activation markers, MPV, PDW, MPM and PMDW that 
increase with platelet size. 
 
Despite the limitations of MPV, PDW, MPM and PMDW as platelet activation 
markers in the CKCS, the association of these indices with CVHD variables 
were similarly explored using multiple regression analyses (see Sections 
4.5.3 through to 4.5.6).  Heart disease indices did not have a significant 
influence on MPV or PDW in the multiple regression analyses. There was 
however a weak negative influence of jet size in the MPM multiple regression 
analysis (possibly consistent with increased platelet degranulation with 
advancing CVHD); and a weak positive influence of murmur grade in the 
PMDW multiple regression analysis (possibly consistent with increased 
variation in platelet granular mass/increased platelet activation with 
advancing heart disease). Since jet size and murmur grade were only weak 
components of their respective models however it is important not to over–
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emphasis the role played by each. As described above, a limitation in the 
present study is that the presence of inherently large platelets in the CKCS 
may reduce the sensitivity of MPV, PDW, MPM and PMDW for the detection 
of platelet activation in the CKCS. 
 
The results of the present study support that of previous studies which 
reported that CVHD is common in the CKCS. There was at least minimal 
MVR (on colour-flow Doppler echocardiography) in the vast majority (86 of 
89 i.e. 97%) of CKCS, and a left apical systolic murmur in 47% of CKCS 
aged 6 years or less. These results are similar to previous studies which 
report ultrasonographic evidence of MVP in 97% of CKCS greater than three 
years of age (Pedersen et al. 1999a) and a murmur in half of all CKCS by 
age 6 - 7 years (Pedersen et al. 1999a, Chetboul et al. 2004). 
 
Because of the high proportion of dogs with MVR, lack of a significant 
association between indicators of heart disease severity and indices of 
platelet activation could also have been explained by the activation of 
platelets in almost all dogs. This was considered unlikely because the MPC 
concentration was higher in CKCS, compared with concentrations in healthy 
control dogs, which suggested a lack of platelet activation. It was also 
possible that activated platelets were removed from circulation, leaving a 
residual population of platelets with a relatively higher MPC concentration. 
However, platelet activation in humans is proportional to the severity of MVR 
(Tse et al. 1997, Icli et al. 2013), and in the present study, a relationship 
between indicators of heart disease severity and MPC concentration would 
have been expected, regardless of the direction of change. 
 
The anticoagulant EDTA was chosen for analysis with the Advia 120, 
because it is the preferred anticoagulant for determining differential blood 
counts with haematology analyses, principally for its cell preservation 
properties (Macey et al. 2002). In people however, the latter study concluded 
that an anticoagulant consisting of a combination of citrate, theophylline, 
adenosine and dipyridamole (CTAD) and EDTA was best for platelet 
activation assessment. More specifically they concluded that blood collected 
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into combined CTAD and EDTA, stored at 4 degrees Celcius, and analysed 
between 60 and 180 minutes later, facilitated maximum platelet sphering 
without concurrent artefactual platelet activation (Macey et al. 2002). In dogs 
the use of combined CTAD and EDTA has not been assessed and the 
optimal anticoagulant for assessment of MPC concentration has not been 
determined. 
 
The prevalence of thrombocytopenia, in the present study (i.e. 21%, as 
assessed by blood smear estimate or Advia 120), was similar to that 
reported in previous studies (i.e. 22-56%, as assessed by manual and blood 
smear estimate platelet counts) (Eksell et al., 1994, Olsen et al., 2001, 
Pedersen et al., 2002, Cowan et al., 2004, Olsen et al., 2004, Singh and 
Lamb, 2005). 
 
The lower prevalence of macrothrombocytosis in CKCS in the present study 
(7%, as assessed by blood smear) compared to that previously reported (30 
and 33%, as assessed by blood smear and electron microscopy 
respectively) (Cowan et al., 2004, Singh and Lamb, 2005), may reflect a true 
lower prevalence of macrothrombocytosis in the cohort of CKCS assessed, 
or subjectivity of the blood smear classification criterion. On the other hand, 
the higher prevalence of macrothrombocytosis as assessed by the Advia 120 
in the present study (22%), is likely due to the Advia 120’s less stringent 
method of macrothrombocyte assessment.  
 
The most stringent method of macrothrombocyte assessment involves only 
counting platelets as large as or larger than an erythrocyte on a blood smear. 
Since canine erythrocyte diameter is approximately 7µm (Rizzi et al. 2010), 
only platelets approximately 7µm or greater in diameter are counted as 
macrothrombocytes. In contrast, the previous definition of a 
macrothrombocyte using electron microscopy was less strict, with any 
platelets with a diameter of 3µm or greater counted as macrothrombocytes 
(Cowan et al. 2004).  The Advia 120 is also less strict than blood smear 
estimation in classifying macrothrombocytes, counting all platelets with a 
volume 21 to 60 fL as large platelets (macrothrombocytes); noting that the 
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lower limits of the Advia 120 reference interval for large platelet volume (21 
fL) is approximately one third the lower reference interval for erythrocyte 
volume (62.7fL) (Moritz et al. 2004). The true prevalence of 
macrothrombocytopenia could have been achieved by assessment of the 
mutation (homozygous, heterozygous or clear) in the present population of 
CKCS. 
 
Two of 39 control dogs had a platelet count of less than 200 x 109/L. Both 
dogs were Greyhounds, a breed known to have a lower reference interval for 
platelets, similar to other sight hounds. In both dogs, as expected, the MPV 
was within reference intervals.  
 
Platelet aggregates were visually identified in 44 of 89 (49%) CKCS. In 1 
previous study (Koplitz et al. 2001), 26 blood samples were collected by 
experienced phlebotomists from a jugular vein of cooperative dogs and 
expediently transferred to anticoagulant. Despite use of this technique, at 
least mild platelet aggregation was observed in 14 (54%) samples. In theory, 
platelet aggregation during or after blood collection has the potential to 
activate platelets and alter MPC concentration. A resultant lower MPC 
concentration would be expected with a decreasing platelet count, rather 
than the inverse relationship that was observed in the present study. 
Alternatively, a lower platelet count and higher MPC concentration could be 
expected if activated platelets preferentially clumped, which would result in a 
residual platelet population with a higher MPC concentration. However, MPC 
concentrations were not significantly different between dogs with and without 
platelet aggregation (see Section 4.4.5). 
 
This present study showed a poor strength of agreement between the visual 
detection of platelet clumping and automated platelet clump flag. The APCC 
flagged platelet clumps in 26/45 samples without visually detected clumps 
and failed to flag platelet clumps in 18/44 samples with visually detected 
clumps in smears. An increased clump size did not result in an improved 
ability of the APCC to detect clumps. Overall, the present study results 
suggested that the APCC is a poor indicator of clumping in dogs and a blood 
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smear assessment should be performed to verify the presence or absence of 
platelet clumping. Only one other canine study (Stokol and Erb 2007) has 
assessed the validity of APCC for the detection of platelet clumps (using a 
population of dogs with neoplasia), and reported a poorer sensitivity, but 
better specificity than that obtained in the present study (see Section 4.4.5). 
The sensitivity and specificity of the two studies cannot be directly compared 
because the platelet clumping categories were not standardised. 
 
Several differences were identified between platelet indices in the CKCS and 
control groups. Unsurprisingly, platelet count was significantly lower, and 
MPV significantly higher in the CKCS group, which reflects the presence of 
macrothrombocytopenia in several CKCS. This was supported by higher 
MPV values in CKCS with lower platelet counts (Figure 4.17). 
 
Macrothrombocytopenia in CKCS is associated with a nonsynonymous 
single nucleotide polymorphism in the gene encoding β1-tubulin, which is 
believed to lead to altered proplatelet production by megakaryocytes (Davis 
et al. 2008). Although the β-1 isolate of β-tubulin is considered to be 
megakaryocyte specific, it may be upregulated in other tissues under 
pathological conditions. Although densification of microtubular networks 
within cardiomyocytes contributes to contractile dysfunction in subjects with 
experimentally induced heart disease, it is unclear whether this altered β-
tubulin structure plays a role in the pathogenesis of naturally occurring CVHD 
in CKCS (Tsutsui et al. 1993, Koide et al. 2000). 
 
The PCT was significantly lower for the CKCS group. However, the PCT for 
the optical-based haematology analyser was determined indirectly by use of 
the equation PCT = platelet count X MPV/10,000. The optical-based 
haematology analyser used light-scatter signals acquired at 2 angles that 
were converted into volume and refractive indices via calculation with the Mie 
light-scatter theory (Briggs et al. 2007). A graphic representation of the 2 
light-scatter measurements was created, and platelets were identified in the 
region corresponding to a volume of 1 to 60 fL and refractive index of 1.35 to 
1.40. The platelet-scatter cytogram displayed cells with volumes of 0 to 30 fL. 
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The large platelet area of the red blood cell-scatter cytogram displayed large 
platelets with volumes between 31 and 60 fL. The reported platelet count 
was the sum of platelets and large platelets identified in the platelet- and red 
blood cell-scatter cytograms, respectively. It has been suggested that the 
platelet algorithm for the optical-based haematology analyser may deliber-
ately exclude large platelets from analysis if the hypochromic-macrocytic flag 
results in misclassification of large platelets as small red blood cells, with a 
resultant lower platelet count and derived PCT (Tvedten et al. 2012). Such 
misclassification of platelets as a result of macrothrombocytopenia could 
explain the lower PCT derived for the CKCS. Despite a large number of 
CKCS with thrombocytopenia, the majority of CKCS had PCT within 
reference interval, consistent with adequate platelet volume/mass (due to 
larger platelet size/higher MPV) despite the lower platelet counts. This 
finding suggests that PCT may aid in the differentiation between inherited 
macrothrombocytopenia and significant disease-related thrombocytopenia in 
the CKCS breed. 
 
A greater MPC concentration within CKCS was consistent with interbreed 
variation. To the author’s knowledge, this has not been previously described 
in dogs. However, lower platelet aggregation responses have been reported 
in CKCS relative to healthy Beagles, and higher responses have been 
reported relative to a group of Cairn Terriers, Labrador Retrievers, and 
Boxers, which suggests that breed factors should be considered when 
interpreting results of platelet function tests (Cowan et al. 2004, Nielsen et al. 
2007). In contrast to the human literature (Giacomini et al., 2001), the 
present study did not find a decrease in MPC concentration with age. 
 
The MPV of the CKCS in the present study was higher than that of the 
control dogs, as expected, due to the inherited large platelet size in this 
breed. The higher PDW in the CKCS compared to the control dogs was 
consistent with increased variation in platelet size in the CKCS. The higher 
MPM in the CKCS, compared with the control dogs is likely due to higher 
granule content per CKCS platelet. The latter result suggests that larger 
platelets contain more granules than smaller platelets. The PMDW of the 
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CKCS was significantly higher than that of the control population, consistent 
with increased variation in granule content in the CKCS population, likely 
reflecting the presence of both small and large circulating platelets in the 
CKCS breed. The majority of CKCS and control dogs had HCT values within 
reference intervals. Interestingly, the CKCS HCT values were tightly 
clustered around the low to mid limits of the reference interval, whereas the 
HCT of the control dogs were more evenly distributed across the reference 
interval. This result most likely represents (low intra-breed) variance in the 
CKCS group.  
 
Interestingly, platelet count had a small but significant effect on MPC 
concentration and PCDW in the multiple regression models. The MPC 
concentration was lower and PCDW higher with increasing platelet counts. 
Both of these findings suggest greater platelet activation at higher counts. 
Investigators of a previous study (Olsen et al. 2001), found higher maximal 
platelet aggregation responses for CKCS with platelet counts greater than 
100 x 109/L, compared with responses for healthy control dogs and CKCS 
with less than 100 x 109/L. The reasons for these associations are not 
known. One possible theory is that in the present study, there was a 
subclinical stimulus, unassociated with heart disease, for concurrent platelet 
activation and platelet formation in the population of CKCS assessed. It was 
not due to the fact that there was more clumping at higher platelet counts 
because 5/7 data points with the highest counts and lowest MPC 
concentrations represented samples without platelet clumping (see Section 
4.5.2). Furthermore this association was not due to larger platelets being 
denser because there was no association between MPC concentration and 
MPV.  Additional studies are necessary to compare the effects of platelet 
count and macrothrombocytopenia on markers of platelet activation. 
 
In addition to MPC concentration and PCDW, platelet count had a small but 
significant influence on other dependent variables including closure time, 
MPV, PDW, MPM and PMDW in the multiple regression models. For some 
dependent variables such as PDW and PMDW, the relationship with platelet 
count was complex and could not be described as simply positive or 
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negative. The influence of platelet count in the closure time model was weak 
(partial R2 = 0.02, P = 0.026), consistent with adequate platelet function 
despite some very low platelet counts. Similarly in a previous study platelet 
count had no significant influence on closure time in CKCS (Tarnow et al. 
2003), consistent with the breed’s larger platelet size and enhanced function 
per platelet. The negative association of MPV with platelet count was 
physiologically expected. It reflects the fact that, assuming consistent 
receptor density, it is the number of TPO receptors, not platelet number that 
determines platelet production and permits maintenance of PCT within 
reference intervals (refer to Section 1.3.1.4). The relationship of PDW and 
platelet count was complex (Figure 4.29). There was least variation in 
platelet size in CKCS with platelet counts less than 100 x 109/L and greater 
than 250 x 109/L, and the most variation in platelet size in dogs with platelet 
counts 100 to 250 x 109/L. This result demonstrates that CKCS with the 
lowest platelet counts (i.e. less than 100 x 109/L) and highest counts (i.e. 
greater than 250 x 109/L) have little variation in platelet size (due to a high 
percentage of large platelets and normal platelets in circulation respectively). 
Conversely dogs with platelet counts 100 to 250 x 109/L are most likely to 
have a combination of large and normal sized platelets. MPM was higher at 
lower platelet counts, and MPM decreased as platelet count increased 
(Figure 4.30). This result was likely due to larger platelets having more 
granules than smaller platelets (since lower platelet counts are associated 
with larger platelet size). To test this hypothesis, MPM was subsequently 
plotted against MPV (Figure 4.31). A linear, positive relationship between 
MPM and MPV was obtained and confirmed increased granule mass with 
increased platelet size. A complex relationship between PMDW and platelet 
count (Figure 4.32) was established. There was lowest PMDW (least 
variation in mass of platelet component) in CKCS with platelet counts greater 
than 250 x 109/L and platelet size less than 100 x 109/L, likely due to the fact 
that these two groups of CKCS have the least variation in platelet size i.e. 
either majority small or large platelets respectively. The most variation in 
mass of platelet component was found in CKCS with platelet counts 100 to 
250 x 109/L, the population of CKCS most likely to have a combination of 
large and normal sized platelets.  
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Dogs in the present study were apparently healthy; however, subclinical 
diseases could not be excluded and may have affected platelet activation in-
dices in some cases. For example, increased platelet activation has been 
described in dogs with malignant neoplasia (McNiel et al. 1997), and internal 
neoplasia could not be excluded in the dogs of the present study without ad-
ditional diagnostic imaging. Although such unrecognised diseases could 
have affected platelet activation indices in some dogs, it was thought unlikely 
to affect results of the present study because of the expected low prevalence 
of such diseases in dogs with no clinical signs of illness. 
 
Limitations of the present study included inclusion of a small number of 
CKCS without MVR and the fact there were no dogs with congestive heart 
failure. Unaffected healthy CKCS would have been the ideal control group for 
assessment of the effects of MVR on markers of platelet activation. However, 
given the high prevalence of MVR in this breed, obtaining a large number of 
unaffected CKCS would have been difficult. The inclusion of dogs with 
congestive heart failure might have confounded the interpretation of results 
because several commonly used drugs, including diuretics and angiotensin-
converting enzyme inhibitors, can reportedly affect platelet function in 
humans, (Kribben et al. 1988, Schäfer et al. 2003) and the same may be true 
in dogs. 
 
In the present study, platelet activation, as assessed on the basis of MPC 
concentration and PCDW, was not a feature of subclinical CVHD in CKCS. 
Increased closure times in CKCS with a regurgitant jet size greater than 50% 
likely reflects quantitative and qualitative changes in VWF, as previously 
described (Tarnow et al. 2004). Significant differences in several platelet 
variables, including platelet count, MPV, analyser-derived PCT, MPC 
concentration, and PCDW, were detected between CKCS and dogs of other 
breeds. Such interbreed variation must be considered when interpreting 
results.  
 
Further studies are required to investigate potential platelet activation in 
other breeds with CVHD as well as in other types of heart disease. It would 
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also be interesting to evaluate platelet activation in dogs with congestive 
heart failure (i.e. those most severely affected with turbulent high-velocity 
blood flow and fluid shear stress). Additional studies are indicated to identify 
the anticoagulant of choice for assessment of platelet indices such as MPC 
concentration, with the end goal to facilitate optimal clinical application. The 
identified interbreed variability in MPC concentration suggests that the 
requirement for breed-specific reference intervals should be investigated. 
Finally, the identified associations between markers of platelet activation 
(MPC concentration and PCDW) and platelet count warrant further research, 
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7.5 Appendix 5: Control dog Signalment, platelet indices and haematocrit 
 
